WO2003002596A2 - Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders - Google Patents

Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders Download PDF

Info

Publication number
WO2003002596A2
WO2003002596A2 PCT/EP2002/007133 EP0207133W WO03002596A2 WO 2003002596 A2 WO2003002596 A2 WO 2003002596A2 EP 0207133 W EP0207133 W EP 0207133W WO 03002596 A2 WO03002596 A2 WO 03002596A2
Authority
WO
WIPO (PCT)
Prior art keywords
residue
acid
alkyl
amino acid
dpiv
Prior art date
Application number
PCT/EP2002/007133
Other languages
French (fr)
Other versions
WO2003002596A3 (en
Inventor
Hans-Ulrich Demuth
Torsten Hoffmann
Ulrich Heiser
Konrad Glund
Stephan VON HÖRSTEN
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10150203A external-priority patent/DE10150203A1/en
Priority claimed from DE10154689A external-priority patent/DE10154689A1/en
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Priority to AU2002328306A priority Critical patent/AU2002328306B8/en
Priority to DE60224879T priority patent/DE60224879D1/en
Priority to JP2003508976A priority patent/JP2004534836A/en
Priority to CA002424645A priority patent/CA2424645A1/en
Priority to EP02762309A priority patent/EP1399471B1/en
Publication of WO2003002596A2 publication Critical patent/WO2003002596A2/en
Priority to NO20030895A priority patent/NO20030895D0/en
Publication of WO2003002596A3 publication Critical patent/WO2003002596A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

  • the present invention relates to inhibitors of dipeptidyl peptidase IV and dipeptidyl peptidase IV-like enzyme activity and, more particularly, pharmaceutical compositions containing said compounds, and the use of said compounds for the treatment of central nervous disorders, immune and autoimmune disorders.
  • the present invention especially provides a method for the treatment of multiple sclerosis.
  • Dipeptidyl peptidase IV is a serine protease which cleaves N-terminal dipeptides from a peptide chain containing, preferably, a proline residue in the penultimate position.
  • DPIV is responsible for inactivating glucagon-like peptide-1 (GLP-1 ) and glucose-dependent insulinotropic peptide also known as gastric-inhibitory peptide (GIP). Since GLP-1 is a major stimulator of pancreatic insulin secretion and has direct beneficial effects on glucose disposal, in WO 97/40832 and US 6,303,661 inhibition of DPIV and DPIV-like enzyme activity was shown to represent an attractive approach for treating non-insulin-dependent diabetes meilitus (NIDD ).
  • NIDD non-insulin-dependent diabetes meilitus
  • the present invention provides a new use of DPIV-inhibitors for the prophylaxis and treatment of conditions mediated by inhibition of DPIV and DPIV-like enzymes, in particular the prophylaxis and treatment of neuronal disorders and immune disorders including multiple sclerosis, and pharmaceutical compositions e.g. useful in inhibiting DPIV and DPIV-like enzymes and a method of inhibiting said enzyme activity.
  • This invention relates to a method of treatment, in particular to a method for the prophylaxis and treatment of central nervous disorders, immune and autoimmune disorders, especially multiple sclerosis and to compounds and compositions for use in such method.
  • Dipeptidyl peptidase IV (DPIV) is a post-pro
  • DPIV-lnhibitors may be useful for the treatment of impaired glucose tolerance and diabetes mellitus (International Patent Application, Publication Number WO 99/61431 , Pederson RA et al, Diabetes. 1998 Aug; 47(8):1253-8 and Pauly RP et al, Metabolism 1999 Mar; 48(3):385-9).
  • DPIV-lnhibitors comprising an amino acid residue and a thiazolidine or pyrrolidine group, and salts thereof, especially L-tf7reo-isoleucyl thiazolidine, L-a//o- isoleucyl thiazolidine, L-f ⁇ reo-isoleucyl pyrrolidine, L-a//o-isoleucyl thiazolidine, L-a//o- isoleucyl pyrrolidine, and salts thereof.
  • low molecular weight dipeptidyl peptidase IV inhibitors are agents such as tetrahydroisoquinolin-3-carboxamide derivatives, N-substituted 2- cyanopyroles and -pyrrolidines, N-(N'-substituted glycyl)-2-cyanopyrrolidines, N- (substituted glycyl)-thiazoIidines, N-(substituted glycyl)-4-cyanothiazo ⁇ dines, amino- acyl-borono-prolyl-inhibitors and cyclopropyl-fused pyrrolidines.
  • Inhibitors of dipeptidyl peptidase IV are described in US 6,011 ,155; US 6,107,317; US 6,110,949; US 6,124,305; US 6,172,081 ; WO 99/61431 , WO 99/67278, WO 99/67279, DE 198 34 591 , WO 97/40832, DE 196 16 486 C 2, WO 98/19998, WO 00/07617, WO 99/38501, WO 99/46272, WO 99/38501 , WO 01/68603, WO 01/40180, WO 01/81337, WO 01/81304, WO 01/55105, WO 02/02560 and WO 02/14271 , the teachings of which are herein incorporated by reference in their entirety concerning these inhibitors, their uses, definition and their production.
  • DPIV-like enzymes relates to structurally and/or functionally DPIV/CD26-related enzyme proteins (Sedo & Malik, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta 2001 , 36506: 1-10).
  • this small group of enzymes has evolved during evolution to release H-Xaa-Pro-Dipeptides and H-Xaa-Ala-Dipeptides from N-terminus of oligo- or polypeptides. They show the common feature, that they accomotate in the Pro-position also Al, Ser, Thr and other amino acids with small hydrophobic side- chains as, Gly or Val.
  • the hydrolytic efficacy is ranked Pro>Ala» Ser, Thr » Gly, Val. Same proteins have been only available in such small quantities, that only the post- Pro or post-Ala cleavage could be established. While the proteins: DPIV, DP II, FAP (Seprase), DP 6, DP 8 and DP 9 are structurally related and show a high sequence homology of , attraction is an extraordinary functional DPIV-like enzyme, characterized by a similar activity and inhibitory pattern.
  • DPIV-like enzymes are disclosed in WO 01/19866, WO 02/34900 and WO02/31134.
  • WO 01/19866 discloses novel human dipeptidyl aminopeptidase 8 (DPP8) with structural und functional similarities to DPIV and fibroblast activation protein (FAP).
  • WO 02/34900 discloses a novel dipeptidyl peptidase 9 (DPP9) with significant homology to the amino acid sequences of DPIV and DPP8.
  • WO 02/31134 discloses three DPIV-like enzymes, DPRP1 , DPRP2 and DPRP3. Sequence analysis revealed, that DPRP1 is identical to DPP8, as disclosed in WO 01/19866, that DPRP2 is identical to DPP9 and that DPRP3 is identical to KIAA1492 as disclosed in WO 02/04610.
  • MS Multiple sclerosis
  • CNS central nervous system
  • the disease appears to be autoimmune in nature, i.e., the body's own immune system is responsible for the damage.
  • the principal target of the autoimmune reaction appears to be Myelin Basic Protein (MBP), although other MS antigens have been proposed.
  • MBP Myelin Basic Protein
  • oligodendrocyte can repair this damage and replace the lost myelin.
  • these cells can also be destroyed in MS and so sufferers may lose the ability to repair the damage over time, which allows the disease to progress.
  • the mechanism of disease progression appears complex and several components of the immune system have been linked to the disease. While the underlying tissue damage appears to result predominantly from a T cell mediated response, antibodies against MS antigens are often present in the cerebrospinal fluid (CSF) and at active lesions. Antibodies are not normally present in the CSF and some disruption of the blood brain barrier (BBB), a protective membrane around the CNS, must also occur to allow antibodies, T cells and macrophages to enter the CSF. This change in the permeability of the BBB appears to be one of the defining events in the development of MS.
  • BBB blood brain barrier
  • Activated macrophages secrete pro-inflammatory cytokines such as TNF- ⁇ and interferon- ⁇ , leading to the production of destructive enzymes and free radicals.
  • the disease can also affect a number of targets.
  • other cells such as astrocytes and microglia can be attacked, forming discreet regions of damage known as plaques or lesions.
  • the lesions are also known as scleroses (hence the name) and can occur in both the brain and the spinal cord.
  • the sites of the lesions tend to be near blood vessels and are commonly found on the optic nerve, cerebellum, periventricular regions and spinal cord.
  • the present invention provides a new use of DPIV-inhibitors.
  • the compounds of formulas 1 to 12, and their corresponding pharmaceutically acceptable acid addition salt forms are useful in treating conditions mediated by DPIV or DPIV-like enzymes, such as immune, autoimmune or central nervous system disorders selected from the group consisting of strokes, tumors, ischemia, Parkinson's disease, and migraines.
  • the compounds of the present invention are useful for the treatment of multiple sclerosis.
  • FIG 1 Illustrates the clinical course of experimental autoimmune encephalomyelitis (EAE).
  • EAE experimental autoimmune encephalomyelitis
  • Figure 2 Illustrates the clinical course of experimental autoimmune encephalomyelitis (EAE) in isoleucyl thiazolidine fumarate treated rats split by days 10-15 post immunization. Separate one factor ANOVAs revealed significant disease-aggravating effect at the 1 mg dosage on day 11 and 12 p.i., while the 10mg dose significantly reduced clinical score at day 15 p.i. This indicates that the inhibitor initially tends to aggravate the disease while at later stages it results in an accelerated recovery from disease. Columns represent means ⁇ SEM of the mean clinical score per day. Asterisks indicate significant post-hoc effects in the PLSD test with * ⁇ 0.05 and * * ⁇ 0.001.
  • FIG. 3 Illustrates the clinical course of experimental autoimmune encephalomyelitis (EAE).
  • EAE experimental autoimmune encephalomyelitis
  • Two factor ANOVA for repeated measures revealed significant main effects for the factor treatment and a significant interaction between the factors "treatment” and "clinical score over time” indicating that treatment significantly modulated the course of the disease and furthermore indicating that the different dosage act differentially.
  • moderate dosages act proinflammatory and cause an "early peak" or aggravation of disease.
  • high dose of isoleucyl thiazolidine fumarate clearly improved the clinical course
  • Figure 4 Illustrates the clinical course of experimental autoimmune encephalomyelitis (EAE) in isoleucyl thiazolidine fumarate treated rats split by days 10-15 post immunization. Separate one factor ANOVAs revealed significant disease-aggravating effect at the 1 mg dosage on day 11 and 12 p.i., while the 10mg dose significantly reduced clinical score at day 15 p.i. This indicates that the inhibitor initially tends to aggravate the disease while at later stages it results in an accelerated recovery from disease. Columns represent means ⁇ SEM of the mean clinical score per day. Asterisks indicate significant post-hoc effects in the PLSD test with * ⁇ 0.05 and * * ⁇ 0.001.
  • FIG. 5 Illustrates the clinical course of experimental autoimmune encephalomyelitis (EAE).
  • EAE experimental autoimmune encephalomyelitis
  • Two factor ANOVA for repeated measures revealed significant main effects for the factor treatment and a significant interaction between the factors "treatment” x "clinical score over time” indicating that treatment significantly modulated the course of the disease. All dosages of the DPIV-inhibitor exhibited ant-inflammatory effects with a delay of onset and an improvement of the clinical course.
  • the present invention relates to the area of dipeptidyl peptidase IV (DPIV) inhibition and, more particularly, to a new use of inhibitors of DPIV and DPIV-like enzyme activity for the prevention and treatment of neuronal and immune disorders, in particular for the treatment of multiple sclerosis, and pharmaceutical compositions containing said compounds.
  • DPIV dipeptidyl peptidase IV
  • the present invention relates to dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof, referred to hereinafter as dipeptide compounds.
  • dipeptide compounds in which the amino acid is preferably selected from a natural amino acid, such as, for example, leucine, valine, glutamine, glutamic acid, proline, isoleucine, asparagines and aspartic acid.
  • the dipeptide compounds used according to the invention exhibit at a concentration (of dipeptide compounds) of 10 ⁇ M, indicated in Table 7, a reduction in the activity of dipeptidyl peptidase IV or DPIV-analogous enzyme activities of at least 10 %, especially of at least 40 %. Frequently a reduction in activity of at least 60 % or at least 70 % is also required. Preferred effectors may also exhibit a reduction in activity of a maximum of 20 % or 30 %.
  • Preferred compounds are L-a//o-isoleucyl thiazolidine, L-#7reo-isoleucyl pyrrolidine and salts thereof, especially the fumaric salts, and L-a//o-isoleucyl pyrrolidine and salts thereof.
  • Especially preferred compounds are glutaminyl pyrrolidine and glutaminyl thiazolidine of formulas 1 and 2:
  • the salts of the dipeptide compounds can be present in a molar ratio of dipeptide (- analogous) component to salt component of 1 : 1 or 2 : 1.
  • a salt is, for example, (lle-Thia) 2 fumaric acid.
  • the present invention provides peptide compounds of formula 3 useful for competitive modulation of dipeptidyl peptidase IV catalysis:
  • A, B, C, D and E are independently any amino acid moieties including proteinogenic amino acids, non-proteinogenic amino acids, L-amino acids and D- amino acids and wherein E and/or D may be absent with additional conditions as hereinafter detailed:
  • A is any amino acid except a D-amino acid
  • B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxyiic acid and pipecolic acid,
  • C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine,
  • D is any amino acid or missing
  • E is any amino acid or missing
  • or C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid, except N-alkylated amino acids, e.g. N-methyl valine and sarcosine and except a D- amino acid,
  • D is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid and pipecolic acid, and
  • E is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine.
  • amino acids examples include aspartic acid (Asp), glutamic acid (Glu), arginine (Arg), lysine (Lys), histidine (His), glycine (Gly), serine (Ser) and cysteine (Cys), threonine (Thr), asparagine (Asn), glutamine (Gin), tyrosine (Tyr), alanine (Ala), proline (Pro), valine (Val), isoleucine (lie), leucine (Leu), methionine (Met), phenylalanine (Phe), tryptophan (Trp), hydroxyproline (Hyp), beta-alanine (beta-Ala), 2-amino octanoic acid (Aoa), azetidine- (2)-carboxylic acid (Ace), pipecolic acid (Pip), 3-amino propionic, 4-amino butyric and so forth, alpha-aminoi
  • t ⁇ -amino acids are e.g.: 5-Ara (aminoraleric acid), 6-Ahx (aminohexanoic acid), 8-Aoc (aminooctanoic aicd), 9-Anc (aminovanoic aicd), 10-Adc (aminodecanoic acid), 11-Aun (aminoundecanoic acid), 12-Ado (aminododecanoic acid).
  • amino acids are: indanylglycine (Igl), indoline-2-carboxylic acid (Idc), octahydroindole-2-carboxylic acid (Oic), diaminopropionic acid (Dpr), diaminobutyric acid (Dbu), naphtylalanine (1-Nal), (2-Nal), 4-aminophenylaIanin (Phe(4-NH 2 )), 4- benzoylphenylalanine (Bpa), diphenylalanine (Dip), 4-bromophenylalanine (Phe(4- Br)), 2-chlorophenylalanine (Phe(2-CI)), 3-chlorophenylalanine (Phe(3-CI)), 4- chlorophenylalanine (Phe(4-CI)), 3,4-chlorophenylalanine (Phe (3,4-CI 2 )), 3- fluorophenylalanine (Phe(3-F)),
  • Proteinogenic amino acids are defined as natural protein-derived ⁇ -amino acids. Non-proteinogenic amino acids are defined as all other amino acids, which are not building blocks of common natural proteins.
  • the resulting peptides may be synthesized as the free C-terminal acid or as the C- terminal amide form.
  • the free acid peptides or the amides may be varied by side chain modifications.
  • Such side chain modifications are for instance, but not restricted to, homoserine formation, pyroglutamic acid formation, disulphide bond formation, deamidation of asparagine or glutamine residues, methylation, t-butylation, t- butyloxycarbonylation, 4-methylbenzylation, thioanysilation, thiocresylation, bencyloxymethylation, 4-nitrophenylation, bencyloxycarbonylation, 2- nitrobencoylation, 2-nitrosulphenylation, 4-toluenesulphonylation, pentafluorophenylation, diphenylmethylation, 2-chlorobenzyloxycarbonylation, 2,4,5- trichlorophenylation, 2-bromobenzyloxycarbonylation, 9- fluor
  • the amino acid moieties A, B, C, D, and E are respectively attached to the adjacent moiety by amide bonds according to standard nomenclature so that the amino-terminus (N-terminus) of the amino acids (peptide) is drawn on the left and the carboxyl-terminus of the amino acid (peptide) is drawn on the right.
  • known peptide substrates of the proline- specific serine protease dipeptidyl peptidase IV in vitro are the tripeptides Diprotin A (lle-Pro-lle), Diprotin B (Val-Pro-Leu) and Diprotin C (Val-Pro-lle).
  • the compounds disclosed here act as substrates of dipeptidyl peptidase IV in vivo in a mammal and, in pharmacological doses, inhibit the physiological turnover of endogenous substrates by competitive catalysis.
  • Particularly preferred compounds of the present invention that are useful as modulators of dipeptidyl peptidase IV and DPIV - like enzymes include those compounds which show Kj-values for DPIV binding, effectively in DPIV inhibition in vivo after i.v. and/or p.o. administration to Wistar rats
  • Peptidylketones of formula 4 are Peptidylketones of formula 4:
  • A is selected from
  • X 1 is H or an acyl or oxycarbonyl group incl. all amino acids and peptide residues
  • X 3 is H or a phenyl or pyridyl residue, unsubstituted or substituted with one, two or more alkyl, alkoxy, halogen, nitro, cyano or carboxy residues
  • X 4 is H or a phenyl or pyridyl residue, unsubstituted or substituted with one, two or more alkyl, alkoxy, halogen, nitro, cyano or carboxy residues
  • X 5 is H or an alkyl, alkoxy or phenyl residue
  • X 6 is H or an al
  • X is selected from: H, OR 2 , SR 2 , NR 2 R 3 , N + R 2 R 3 R 4 , wherein:
  • R 2 stands for acyl residues, which are unsubstituted or substituted with one, two or more alkyl, cycloalkyl, aryl or heteroaryl residues, or for all amino acids and peptidic residues, or alkyl residues, which are unsubstituted or substituted with one, two or more alkyl, cycloalkyl, aryl and heteroaryl residues,
  • R 3 stands for alkyl and acyl functions, wherein R 2 and R 3 may be part of one or more ring structures of saturated and unsaturated carbocyclic or heterocyclic structures,
  • R 4 stands for alkyl residues, wherein R 2 and R 4 or R 3 and R 4 may be part of one or more ring structures of saturated and unsaturated carbocyclic or heterocyclic structures,
  • B stands for: O, S, NR 5 , wherein R 5 is H, an alkyliden or acyl,
  • C, D, E, F, G, H are independently selected from unsubstituted and substituted alkyl, oxyalkyl, thioalkyl, aminoalkyl, carbonylalkyl, acyl, carbamoyl, aryl and heteroaryl residues; and
  • Z is selected from H, or a branched or single chain alkyl residue from C 1 -C 9 or a branched or single chain alkenyl residue from C2-C9, a cycloalkyl residue from C 3 -C 8 , a cycloalkenyl residue from Cs-C , an aryl- or heteroaryl residue, or a side chain selected from all side chains of all natural amino acids or derivatives thereof.
  • R 1 is H, a branched or linear C 1 -C 9 alkyl residue, a branched or linear C 2 -C 9 alkenyl residue, a C 3 -Cs cycloalkyl- , Cs-C cycloalkenyl-, aryl- or heteroaryl residue or a side chain of a natural amino acid or a derivative thereof,
  • R 3 and R 4 are independently selected from H, hydroxy, alkyl, alkoxy, aryloxy, nitro, cyano or halogen,
  • A is H or an isoster of a carbonic acid, like a functional group selected from CN, SO 3 H, CONHOH, PO 3 R 5 R 6 , tetrazole, amide, ester, anhydride, thiazole and imidazole,
  • B is selected from:
  • Y H, Br, Cl, I, NO 2 or CN ,
  • R 10 is H, an acyl, oxycarbonyl or a amino acid residue ,
  • W is H or a phenyl or pyridyl residue, unsubstituted or substituted with one, two or more alkyl, alkoxy, halogen, nitro, cyano or carboxy residues,
  • W 1 is H, an alkyl, alkoxy or phenyl residue
  • Z is H or a phenyl or pyridyl residue, unsubstituted or substituted with one, two or more alkyl, alkoxy, halogen, nitro, cyano or carboxy residues,
  • Z 1 is H or an alkyl residue
  • D is a cyclic C -C alkyl, C 4 -C alkenyl residue which can be unsubstituted or substituted with one, two or more alkyl groups or a cyclic 4-7-membered heteroalkyl or a cyclic 4-7-membered heteroalkenyl residue,
  • X 2 is O, NR 6 , N + (R 7 ) 2 , or S,
  • X 3 to X 12 are independently selected from CH 2 , CR 8 R 9 , NR 6 , N + (R 7 ) 2 , O, S, SO and SO 2 , including all saturated and unsaturated structures,
  • R 6 , R 7 , R 8 , R 9 are independently selected from H, a branched or linear CrCg alkyl residue, a branched or linear C2-C 9 alkenyl residue, a C3-C 8 cycloalkyl residue, a C 5 - C 7 cycloalkenyl residue, an aryl or heteroaryl residue, with the following provisions:
  • Formula 6 X 6 is CH if A is not H
  • Formula 7 X 10 is C if A is not H
  • Formula 8 X 7 is CH if A is not H
  • Formula 9 X 12 is C if A is not H.
  • acyl can denote a C- ⁇ - 20 acyl residue, preferably a C-t- ⁇ acyl residue and especially preferred a C ⁇ -4 acyl residue
  • cycloalkyl can denote a C3- 1 2 cycloalkyl residue, preferably a C , C 5 or C ⁇ cycloalkyl residue
  • carbocyclic can denote a C3- 12 carbocyclic residue, preferably a C 4 , C 5 or C ⁇ carbocyclic residue.
  • Heteroaryl is defined as an aryl residue, wherein 1 to 4, preferably 1 , 2 or 3 ring atoms are replaced by heteroatoms like N, S or O.
  • Heterocyclic is defined as a cycloalkyl residue, wherein 1, 2 or 3 ring atoms are replaced by heteroatoms like N, S or O.
  • “Peptides” are selected from dipeptides to decapeptides, preferred are dipeptides, tripeptides, tetrapeptides and pentapeptides. The amino acids for the formation of the “peptides” can be selected from the those listed above.
  • the problem to be solved was, moreover, to provide compounds that can be used for targeted influencing of locally limited pathophysiological and physiological processes.
  • the problem of the invention especially consists in obtaining locally limited inhibition of DPIV or DPIV-analogous activity for the purpose of targeted intervention in the regulation of the activity of locally active substrates.
  • This problem is solved according to the invention by compounds of the general formula (12)
  • A is an amino acid having at least one functional group in the side chain
  • B is a chemical compound covalently bound to at least one functional group of the side chain of A
  • C is a thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine group amide-bonded to A.
  • the compounds can be used for reducing immune, autoimmune or central nervous system related disorders.
  • compositions comprising at least one compound of the general formula (12) and at least one customary adjuvant appropriate for the site of action.
  • A is an ⁇ -amino acid, especially a natural ⁇ -amino acid having one, two or more functional groups in the side chain, preferably threonine, tyrosine, serine, arginine, lysine, aspartic acid, glutamic acid or cysteine.
  • B is an oligopeptide having a chain length of up to 20 amino acids, a polyethylene glycol having a molar mass of up to 20 000 g/mol, an . optionally substituted organic amine, amide, alcohol, acid or aromatic compound having from 8 to 50 C atoms.
  • alkyl can denote a C ⁇ _5o alkyl group, preferably a C 6- 3o alkyl group, especially a C 8-12 alkyl group; for example, an alkyl group may be a methyl, ethyl, propyl, isopropyl or butyl group.
  • alk for example in the expression “alkoxy”, and the expression “alkan”, for example in the expression “alkanoyl”, are defined as for “alkyl”; aromatic compounds are preferably substituted or optionally unsubstituted phenyl, benzyl, naphthyl, biphenyl or anthracene groups, which preferably have at least 8 C atoms;
  • alkenyl can denote a C2-10 alkenyl group, preferably a C 2 - 6 alkenyl group, which has the double bond(s) at any desired location and may be substituted or unsubstituted;
  • alkynyl can denote a C 2- ⁇ o alkynyl group, preferably a C 2 - 6 alkynyl group, which has the triple bond(s) at any desired location and may be substituted or unsubstituted;
  • substituted or substituent can denote any desired substitution by one or more, preferably
  • the compounds of formula (12) can still bind to the active centre of the enzyme dipeptidyl peptidase IV and analogous enzymes but are no longer actively transported by the peptide transporter PepT1.
  • the resulting reduced or greatly restricted transportability of the compounds according to the invention leads, in ideal manner, to local or site directed inhibition of DPIV and DPIV-like enzyme activity.
  • the compounds of formula (12) or the other compounds used in accordance with the invention can be present or used, respectively, in the form of racemates or in the form of enantiomerically pure compounds, preferably in the L-threo or L-allo form with respect to part A of formula (12).
  • the compounds of formula (12) inhibit DPIV or DPIV-like enzyme activity in the body of a mammal in a site specific manner. It is accordingly possible to influence local physiological and pathophysiological conditions (inflammation, psoriasis, arthritis, immune, autoimmune diseases, allergies, but also central nervous system related disorders) effectively and with dramatically reduced side-effects.
  • Preferred compounds of formula (12) are compounds, wherein the oligopeptides have chain lengths of from 3 to 15, especially from 4 to 10, amino acids, and/or the polyethylene glycols have molar masses of at least 250 g/mol, preferably of at least 1500 g/mol and up to 15 000 g/mol, and/or the optionally substituted organic amines, amides, alcohols, acids or aromatic compounds have at least 12 C atoms and preferably up to 30 C atoms.
  • the compounds of the present invention can be converted into and used as acid addition salts, especially pharmaceutically acceptable acid addition salts.
  • the pharmaceutically acceptable salt generally takes a form in which an amino acids basic side chain is protonated with an inorganic or organic acid.
  • Representative organic or inorganic acids include hydrochloric, hydrobromic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toulenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. All pharmaceutically acceptable acid addition salt forms of the compounds of formulas 1 and 12 are intended to be embraced by the scope
  • the present invention further includes within its scope prodrugs of the compounds of this invention.
  • prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the desired therapeutically active compound.
  • the use of the present invention shall encompass the treatment of the various disorders described with prodrug versions of one or more of the claimed compounds, which convert to the above specified compound in vivo after administration to the subject.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985 and the patent applications DE 198 28 113 and DE 19828 114, which are fully incorporated herein by reference.
  • the compounds or prodrugs according to this invention may accordingly exist as enantiomers. Where the compounds or prodrugs possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms of the compounds or prodrugs may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e. hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
  • the compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
  • the compounds and prodrugs of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms are useful in inhibiting DPIV and DPIV - like enzyme activity.
  • the ability of the compounds and prodrugs of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms to inhibit DPIV and DPIV - like enzyme activity may be demonstrated employing the DPIV activity assay for determination of the K ⁇ - values and the ICso-values in vitro, as described in examples 7 and 8.
  • the ability of the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms to inhibit DPIV in vivo may be demonstrated by oral or intravasal administration to Wistar rats, as described in example 11.
  • the compounds of the present invention inhibit DPIV activity in vivo after both, oral and intravasal administration to Wistar rats.
  • DPIV is present in a wide variety of mammalian organs and tissues e.g. the intestinal brush-border (Gutschmidt S. et al., "In situ" - measurements of protein contents in the brush border region along rat jejunal villi and their correlations with four enzyme activities. Histochemistry 1981 , 72 (3), 467-79), exocrine epithelia, hepatocytes, renal tubuli, endothelia, myofibroblasts (Feller A.C. et al., A monoclonal antibody detecting dipeptidylpeptidase IV in human tissue. Virchows Arch. A. Pathol. Anat. Histopathol.
  • Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J. Immunol. 1996, 156 (5): 1714-21).
  • the compounds and prodrugs of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms are able to inhibit DPIV in vivo.
  • all molecular forms, homologues and epitopes of DPIV from all mammalian tissues and organs, also of those, which are undiscovered yet, are intended to be embraced by the scope of this invention.
  • DPIV was originally believed to be the only membrane-bound enzyme specific for proline as the penultimate residue at the amino-terminus of the polypeptide chain.
  • DPIV-like enzymes which are identified so far, are e.g.
  • fibroblast activation protein ⁇ dipeptidyl peptidase IV ⁇ , dipeptidyl aminopeptidase-like protein, N-acetylated ⁇ -linked acidic dipeptidase, quiescent cell proline dipeptidase, dipeptidyl peptidase II, attractin and dipeptidyl peptidase IV related protein (DPP 8), and are described in the review article by Sedo & Malik (Sedo & Malik, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta 2001 , 36506: 1-10).
  • DPIV-like enzymes are disclosed in WO 01/19866, WO 02/34900 and WO02/31134.
  • WO 01/19866 discloses novel human dipeptidyl aminopeptidase 8 (DPP8) with structural und functional similarities to DPIV and fibroblast activation protein (FAP).
  • WO 02/34900 discloses a novel dipeptidyl peptidase 9 (DPP9) with significant homology to the amino acid sequences of DPIV and DPP8.
  • WO 02/31134 discloses three DPIV-like enzymes, DPRP1 , DPRP2 and DPRP3.
  • the ability of the compounds and prodrugs of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms to inhibit DPIV-like enzymes may be demonstrated employing an enzyme activity assay for determination of the Ki-values in vitro as described in example 9.
  • 1.07*10 "5 M ⁇ 3.81 *10 "7 M for glutaminyl thiazolidine.
  • the compounds and prodrugs of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms have only low, if no inhibitory activity against non-DPIV and non-DPIV - like proline specific enzymes.
  • glutaminyl thiazolidine and glutaminyl pyrrolidine exemplarily, no inhibition of dipeptidyl peptidase I and prolyl oligopeptidase was found.
  • prolidase both compounds showed a marked lower efficacy compared to DPIV.
  • the compounds of the present invention are useful in treating conditions mediated by said enzyme activities.
  • the compounds disclosed herein are useful in the treatment of conditions such as immune, autoimmune disorders or central nervous system disorders, selected from the group consisting of strokes, tumors, ischemia, Parkinson's disease, and migraines.
  • the compounds and prodrugs of this invention, and their corresponding pharmaceutically acceptable acid addition salt forms are useful for the treatment of multiple sclerosis.
  • the ability of the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, to alleviate the signs of multiple sclerosis can be determined employing the EAE rat model. The method is described in example 13.
  • the present invention therefore provides a method of preventing or treating a condition mediated by modulation of the DPIV or DPIV - like enzyme activity in a subject in need thereof which comprises administering any of the compounds of the present invention or pharmaceutical compositions thereof in a quantity and dosing regimen therapeutically effective to treat the condition.
  • the present invention includes the use of the compounds and progdrugs of this invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for the preparation of a medicament for the prevention or treatment of a condition mediated by modulation of the DPIV activity in a subject.
  • the compound may be administered to a patient by any conventional route of administration, including, but not limited to, intravenous, oral, subcutaneous, intramuscular, intradermal, parenteral and combinations thereof.
  • the present invention provides formulations for the compounds of formulas 1 to 12, and their corresponding pharmaceutically acceptable prodrugs and acid addition salt forms, in pharmaceutical compositions.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
  • composition is intended to encompass a product comprising the claimed compounds in the therapeutically effective amounts, as well as any product which results, directly or indirectly, from combinations of the claimed compounds.
  • one or more compounds of formulas 1 to 12, or their corresponding pharmaceutically acceptable acid addition salt forms, as the active ingredient is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular.
  • a pharmaceutical carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular.
  • any of the usual pharmaceutical media may be employed.
  • suitable carriers and additives may advantageously include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like;
  • suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desired, tablets may be sugar coated or enteric coated by standard techniques.
  • the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included.
  • Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • the pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above.
  • the pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.01 mg to about 1000 mg (preferably about 5 to about 500 mg) and may be given at a dosage of from about 0.1 to about 300 mg/kg bodyweight per day (preferably 1 to 50 mg/kg/day).
  • compositions are in unit dosage forms from such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
  • the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
  • an insoluble salt of the active compound such as the decanoate salt
  • the principal active ingredient is ideally mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g.
  • a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
  • a pharmaceutically acceptable salt thereof When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is ideally dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules.
  • This solid preformulation composition may then be subdivided into unit dosage forms of the type described above containing from about 0.01 to about 1000 mg, preferably from about 5 to about 500 mg of the active ingredient of the present invention.
  • the tablets or pills of the novel composition can be advantageously coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.
  • the processes for the preparation of the compounds according to the invention give rise to a mixture of stereoisomers
  • these isomers may be separated by conventional techniques such as preparative chromatography.
  • the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
  • the compounds may, for example, be resolved into their components enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base.
  • the compounds may also resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
  • any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis. John Wiley & Sons, 1991 , fully incorporated herein by reference.
  • the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
  • the method of treating conditions modulated by dipeptidyl peptidase IV and DPIV - like enzymes described in the present invention may also be carried out using a pharmaceutical composition comprising one or more of the compounds as defined herein and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition may contain from about 0.01 mg to about 1000 mg, preferably about 5 to about 500 mg, of the compound(s), and may be constituted into any form suitable for the mode of administration selected.
  • Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.
  • compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixirs, emulsions, and suspensions.
  • forms useful for parenteral administration include sterile solutions, emulsions and suspensions.
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • compounds of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen and dosage strength will need to be accordingly modified to obtain the desired therapeutic effects.
  • the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or betalactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and other compounds known within the art.
  • liquid forms are suitable in flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like.
  • suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like.
  • sterile suspensions and solutions are desired.
  • Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
  • the compound of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines using processes well described in the art.
  • Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
  • soluble polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamide-phenol, or polyethyl eneoxidepolyllysine substituted with palmitoyl residue.
  • compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polyactic acid, polyepsilon caprolactone, polyhydroxy butyeric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • biodegradable polymers useful in achieving controlled release of a drug, for example, polyactic acid, polyepsilon caprolactone, polyhydroxy butyeric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • Compounds of this invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever treatment of the addressed disorders is required.
  • the daily dosage of the products may be varied over a wide range from 0.01 to 1.000 mg per adult human per day.
  • the compositions are preferably provided in the form of tablets containing, 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250, 500 and 1000 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.1 mg/kg to about 300 mg/kg of body weight per day.
  • the range is from about 1 to about 50 mg/kg of body weight per day.
  • the compounds may be administered on a regimen of 1 to 4 times per day.
  • Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, bioavailability due to the mode of administration, and the advancement of disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, should generally be considered in adjusting dosages.
  • the compounds or compositions of the present invention may be taken before a meal, while taking a meal or after a meal.
  • N-Methylmorpholine is added dropwise, pivalic acid chloride (on a laboratory scale) or neohexanoyl chloride (on a pilot-plant scale) is added dropwise at constant temperature. The reaction is stirred for a few minutes for activation. N-Methylmorpholine (laboratory scale) and thiazolidine hydrochloride (laboratory scale) are added dropwise in succession, thiazolidine (pilot-plant scale) is added. Working-up in the laboratory is effected in conventional manner using salt solutions, on a pilot-plant scale the batch is purified with NaOH and CH 3 COOH solutions.
  • the removal of the BOC protecting group is carried out using HCI/dioxane (laboratory scale) or H 2 SO (pilot-plant scale).
  • HCI/dioxane laboratory scale
  • H 2 SO pilot-plant scale
  • the hydrochloride is crystallised from EtOH/ether.
  • N-Benzyl-oxycarbonylglutamine (2.02 g, 7.21 mmol) was dissolved in 35 ml THF and brought to -15°C.
  • CAIBE isobutylchloroformiate
  • 4-methylmorpholine 0.795 ml, 7.21 mmol
  • N-t-Butyl-oxycarbonylglutamine (2.0 g, 8.12 mmol) was dissolved in 5ml THF and brought to -15°C.
  • CAIBE isobutylchloroformiate
  • 4-methylmorpholine (0.895 ml, 8.12 mmol) where added and the solution was stirred for 15 min.
  • the formation of the mixed anhydride was checked by TLC (eluent: CHCI 3 /MeOH: 9/1). After warming to -10°C another equivalent 4- methylmorpholine (0.895 ml, 8.12 mmol) and thiazolidine hydrochloride (1.02 g, 8.12 mmol) was added. The mixture was brought to room temperature and stirred overnight.
  • N-t-Butyl-oxycarbonylglutamine (3.0 g, 12.18 mmol) was dissolved in 7ml THF and brought to -15°C.
  • CAIBE isobutylchloroformiate
  • 4-methylmorpholine 1.3 ml, 12.18 mmol
  • the rotation values were recorded at different wavelengths on a "Polarimeter 341" or higher, from the Perkin-Elmer company.
  • the mass spectra were recorded by means of electrospray ionisation (ESI) on an "API 165" or API 365" from the PE Sciex company.
  • ESI electrospray ionisation
  • IT*F isoleucyl thiazolidine fumarate
  • Pre-loaded Fmoc-Yaa-Wang resin (2.8 g/ substitution level 0.57 mmol/g) was deprotected using 20% piperidine/ N,N-dimethylformamide (DMF). After washing with DMF a solution of 2 eq (1.1 g) of Fmoc-Pro-OH were solved in DMF (12ml solvent per gram resin). 2eq (1.04 g) of 2-(1 H-Benzotriazole 1-yl)-1 ,1 ,3,3-tetramethyluronium tetrafluoroborate (TBTU) and 4 eq (1.11 ml) of N,N-diisopropylethylamine (DIEA) were added and placed in the reaction vessel.
  • DIEA N,N-diisopropylethylamine
  • Fmoc protecting group was removed as described above. After that 0.54 mmol of the Boc-amino acid, 0.54 mmol TBTU and 0.108 mmol DIEA in DMF were shaken for 20 min. The coupling cycle was repeated. Finally the peptide resin was washed and dried described above.
  • TFA/H 2 0/triisopropylsilane (TIS) 9.5/0.25/0.25
  • TFA/H 2 0/triisopropylsilane (TIS) 9.5/0.25/0.25
  • TFA/H 2 0/triisopropylsilane (TIS) 9.5/0.25/0.25
  • the pure peptide was obtained by lyophilization, identified by Electrospray mass spectrometry and HPLC analysis.
  • ⁇ -butyl-Gly is defined as:
  • Ser (P) and Ser (Bzl) are defined as phosphorylserine and benzylserine.
  • Tyr (P) is defined as phosporyltyrosine.
  • Boc-Val-OH (3.00g, 13.8mmol) was dissolved in 10ml of dry THF and cooled down to -15°C.
  • CAIBE (1.80ml, 13.8mmol) and NMM (1.52ml, 13.8mmol) where added and the solution was stirred until the formation of the mixed anhydride was complete. Then the mixture was brought to -10°C and NMM (1.52ml, 13.8mmol) was added followed by H-Pro-OMe*HCI (2.29g, 13.8mmol). The mixture was allowed to reach room temperature and left overnight. After removing the solvent and the usual workup the resulting ester 1 was taken without further characterisation.
  • the acid (2eq) was dissolved in DMF and an equimolar amount of KF was added. The suspension was allowed to stir at room temperature for 1 hour. Then the brommethylene (1eq) component was added and the solution was allowed to stir overnight. After that the solvent was removed under vacuum and the resulting oil was dissolved in chloroform and washed with brine. Then the organic layer was separated dried (Na 2 SO ) and the solvent was removed. The product was purified by column chromatography using silica gel and heptane/chloroform.
  • Oxalylchloride (714 ⁇ l, 8.28 mmol) was dissolved in 10 ml of dry dichlormethane and brought to -78°C. Then DMSO (817 ⁇ l, 8.28 mmol) was added dropwise. The solution was stirred for 20 min at -78°C. Then 1 (1.00 g, 4.6 mmol) was added and the mixture was stirred for 20 min. After that TEA (2.58 ml, 18.4 mmol) was added and the mixture was allowed to reach room temperature. The mixture was diluted with hexane/ethylacetate (2/1 v/v) and 10 ml of HCI (10% in water) was added.
  • Boc-Glu-Thia was modified at the ⁇ -carboxylic acid function by introducing radicals of varying size.
  • the radicals were coupled by way of their amino group by forming an amide bond to the ⁇ -carboxylic acid function, with a variety of coupling methods being used depending on the radical.
  • the following amino components were attached to Boc-Glu-Thia using the method stated:
  • the N-terminal Boc protecting groups were cleaved off the compounds described in Table 6.2.2 using method F.
  • the substances modified with Gly derivatives were purified by preparative HPLC separation and are present as trifluoroacetates.
  • the H-Glu(PEG)-Thia was purified on a gel filtration column in the same manner as the Boc-protected precursor.
  • Method A Peptide bond attachment by the mixed anhydride method using CFIBE as activation reagent 10 mmol of N-terminally protected amino acid or peptide are dissolved in 20 ml of absolute THF. The solution is cooled to -15°C + 2°C. With stirring in each case, 10 mmol of N-MM and 10 mmol of chloroformic acid isobutyl ester are added in succession, the stated temperature range being strictly adhered to. After approximately 6 min, 10 mmol of the amino component is added. When the amino component is a salt, a further 10 mmol of N-MM is then added to the reaction mixture. The reaction mixture is then stirred for 2 h in the cold state and overnight at room temperature.
  • reaction mixture is concentrated using a rotary evaporator, taken up in EA, washed with 5 % KH2SO4 solution, saturated NaHCO 3 solution and saturated NaCl solution and dried over NaSO 4 . After removal of the solvent in vacuo, the compound is recrystallized from EA/pentane.
  • Method B Peptide bond attachment by the mixed anhydride method using pivalic acid chloride as activation reagent
  • dipeptidyl peptidase IV from porcine kidney with a specific activity against glycylprolyl- 4-nitroaniline of 37.5 U/mg and an enzyme concentration of 1.41 mg/ml in the stock solution was used.
  • ⁇ -butyl-Gly is defined as:
  • Ser (P) and Ser (Bzl) are defined as phosphorylserine and benzylserine.
  • Tyr (P) is defined as phosporyltyrosine.
  • 100 ⁇ l inhibitor stock solution were mixed with 100 ⁇ l buffer (HEPES pH7.6) and 50 ⁇ l substrate (Gly-Pro-pNA, final concentration 0.4 mM) and preincubated at 30°C. Reaction was started by addition of 20 ⁇ l purified porcine DPIV. Formation of the product pNA was measured at 405 nm over 10 min using the HTS 7000Plus plate reader (Perkin Elmer) and slopes were calculated. The final inhibitor concentrations ranged between 1 mM and 30 nM. For calculation of IC50 GraFit 4.0.13 (Erithacus Software) was used.
  • Ser (P) and Ser (Bzl) are defined as phosphorylserine and benzylserine.
  • Tyr (P) is defined as phosporyltyrosine.
  • DP 11 (3.4.14.2) releases N-terminal dipeptides from oligopeptides if the N- terminus is not protonated (McDonald, J.K., Ellis, S. & Reilly, T.J., 1966, J. Biol. Chem., 241 , 1494-1501 ). Pro and Ala in Pi-position are preferred residues.
  • the enzyme activity is described as DPIV-like activity, but DP II has an acidic pH-optimum. The enzyme used was purified from porcine kidney.
  • Glutaminyl pyrrolidine or glutaminyl thiazolidine were tested for their cross reacting potency against dipeptidyl peptidase I, prolyl oligopeptidase and Prolidase.
  • Dipeptidyl peptidase I (DP I, cathepsin C): DP I or cathepsin C is a lysosomal cysteine protease which cleaves off dipeptides from the N-terminus of their substrates (Gutman, H.R. & Fruton, J.S., 1948, J. Biol: Chem., 174, 851-858) . It is classified as a cysteine protease. The enzyme used was purchased from Qiagen (Qiagen GmbH, Hilden, Germany).
  • the enzyme was diluted lOOOfold in MES buffer pH5,6 (40 mM MES, 4 mM DTT, 4 mM KCI, 2 mM EDTA, 0.015% Brij) and pre-incubated for 30 min at 30°C.
  • the IC 50 -values were calculated using Graphit 4.0.15 (Erithacus Software, Ltd., UK). No inhibition of the DP l enzyme activity by glutaminyl pyrrolidine or glutaminyl thiazolidine was found.
  • POP Prolyl oligopeptidase
  • Prolyl oligopeptidase (EC 3.4.21.26) is a serine type endoprotease which cleaves off peptides at the N-terminal part of the Xaa-Pro bond (Walter, R., Shlank, H., Glass, J.D., Schwartz.l.L. & Kerenyi, T.D., 1971 , Science, 173, 827-829). Substrates are peptides with a molecular weight up to 3000 Da. The enzyme used was a recombinant human prolyl oligopeptidase. Recombinant expression was performed in E. coli under standard conditions as described elsewhere in the state of the art. Assay:
  • 100 ⁇ l glutaminyl pyrrolidine or glutaminyl thiazolidine in an concentration range of 1*10 "4 M - 5 * 10 "8 M were admixed with 100 ⁇ l ⁇ l buffer solution (40 mM HEPES, pH7.6, 0.015% Brij, 1 mM DTT) and 20 ⁇ l POP solution.
  • the assay mixture was preincubated at 30 °C for 15 min.
  • Prolidase (EC 3.4.13.9) was first described by Bergmann & Fruton (Bergmann, M. & Fruton, JS, 1937, J. Biol. Chem. 189-202). Prolidase releases the N-terminal amino acid from Xaa-Pro dipeptides and has a pH optimum between 6 and 9.
  • Prolidase from porcine kidney was solved (1 mg/ml) in assay buffer (20mM NH 4 (CH 3 COO) 2 , 3mM MnCI 2 , pH 7.6). In order to get a fully active enzyme the solution was incubated for 60 min at room temperature.
  • catheters were implanted into the carotid artery of Wistar rats under general anaesthesia (i.p. injection of 0.25 ml/kg b.w. Rompun ® [2 %], BayerVital, Germany and 0.5 ml/kg b.w. Ketamin 10, Atarost GmbH & Co., Twistringen, Germany). The animals were allowed to recover for one week. The catheters were flushed with heparin-saline (100 lU/ml) three times per week. In case of catheter dysfunction, a second catheter was inserted into the contra-lateral carotid artery of the respective rat. After one week of recovery from surgery, this animal was reintegrated into the study. In case of dysfunction of the second catheter, the animal was withdrawn from the study. A new animal was recruited and the experiments were continued in the planned sequence, beginning at least 7 days after catheter implantation.
  • general anaesthesia i.p. injection of 0.25 ml/kg b.w. Rompun ® [2
  • Rats with intact catheter function were administered placebo (1 ml saline, 0.154 mol/l) or test compound via the oral and the intra-vasal (intra-arterial) route. After overnight fasting, 100 ⁇ l samples of heparinised arterial blood were collected at -30, -5, and 0 min. The test substance was dissolved freshly in 1.0 ml saline (0.154 mol/l) and was administered at 0 min either orally via a feeding tube (75 mm; Fine Science Tools, Heidelberg, Germany) or via the intra-vasal route. In the case of oral administration, an additional volume of 1 ml saline was injected into the arterial catheter. In the case of intra-arterial administration, the catheter was immediately flushed with 30 ⁇ l saline and an additional 1 ml of saline was given orally via the feeding tube.
  • the assay mixture for determination of plasma DPIV activity consisted of 80 ⁇ l reagent and 20 ⁇ l plasma sample. Kinetic measurement of the formation of the yellow product 4-nitroaniline from the substrate glycylprolyl-4-nitroaniline was performed at 390 nm for 1 min at 30 °C after 2 min pre-incubation at the same temperature. The DPIV activity was expressed in mU/ml.
  • Example 12 Action Of Side Chain-Modified Glutamylthiazolidines As Non- Readily-Transportable DPIV-lnhibitors
  • Guinea pig MBP 50 ⁇ g/rat was emulsified in Complete Freund ' s adjuvant (CFA) containing heat-killed Mycobacterium tuberculosis (H37Ra; 225 ⁇ g/rat) and injected s.c. at the base of the tail in a total volume of 100 ⁇ l (12).
  • CFA Complete Freund ' s adjuvant
  • H37Ra heat-killed Mycobacterium tuberculosis
  • H37Ra heat-killed Mycobacterium tuberculosis
  • Clinical disease was scored on the following scale: 0.5: partial loss of tail tone; 1.0: complete tail atony; 2.0: hind limb weakness; 2.5: hind limb paralysis of one leg; 3.0: hind limb paralysis of both legs; 3.5: limb paralysis of three legs; 4.0: quadriplegia and moribund status; 5.0: death due to EAE.
  • Guinea pig MBP 50 ⁇ g/rat was emulsified in Complete Freund ' s adjuvant (CFA) containing heat-killed Mycobacterium tuberculosis (H37Ra; 225 ⁇ g/rat) and injected s.c. at the base of the tail in a total volume of 100 ⁇ l (12).
  • CFA Complete Freund ' s adjuvant
  • H37Ra heat-killed Mycobacterium tuberculosis
  • H37Ra heat-killed Mycobacterium tuberculosis
  • Clinical disease was scored on the following scale: 0.5: partial loss of tail tone; 1.0: complete tail atony; 2.0: hind limb weakness; 2.5: hind limb paralysis of one leg; 3.0: hind limb paralysis of both legs; 3.5: limb paralysis of three legs; 4.0: quadriplegia and moribund status; 5.0: death due to EAE. Experiments were terminated on day 21 post immunization (p.i.).
  • This experiment investigated the effects of daily intraperitoneal treatment with the DPIV-inhibitor isoleucyl thiazolidine fumarate over a wide range of dosages in male Lewis rats for 10 days with the treatment being initiated at day 5 post immunization with MBP in CFA.
  • Treatment caused a significant dose-dependent and bimodal treatment effect in this design and model for MS.
  • Low dose (1 mg) of the drug initially aggravates the acute phase of EAE.
  • Moderate dose of isoleucyl thiazolidine fumarate (3 and 10mg) induces an early "first peak" of disease directly after initiation of disease, suggestive for direct pro-inflammatory effects in vivo.
  • High dose of the drug (30mg) exerts clearly a potent anti-inflammatory effect and a delay in the onset of disease.
  • mice Female inbred Lewis rats (n - 50) with a mean body weight of 201 ⁇ 5g, were obtained from Charles River, Germany. Animals were randomly assigned to the different experimental conditions. Rats were housed four per cage under a 12:12 h light: dark cycle (lights off at 18:00 h) and at constant temperature (24°C) in a specific pathogen free air-conditioned colony room with food (Altromin lab chow pellets) and tap water available ad lib. The animals underwent routine cage maintenance once a week.
  • Guinea pig MBP 50 ⁇ g/rat was emulsified in Complete Freund ' s adjuvant (CFA) containing heat-killed Mycobacterium tuberculosis (H37Ra; 225 ⁇ g/rat) and injected s.c. at the base of the tail in a total volume of 100 ⁇ l (12).
  • CFA Complete Freund ' s adjuvant
  • H37Ra heat-killed Mycobacterium tuberculosis
  • H37Ra heat-killed Mycobacterium tuberculosis
  • Clinical disease was scored on the following scale: 0.5: partial loss of tail tone; 1.0: complete tail atony; 1.5: complete tail atony and weakness of one hind limb; 2.0: weakness of both hind limbs; 2.5: hind limb weakness and paralysis of one hind leg; 3.0: paralysis of both hind legs; 3,5: limb paralysis of three legs; 4.0: quadriplegia and moribund status; 5.0: death due to EAE. Experiments were terminated on day 15 post immunization (p.i.).
  • This experiment investigated the effects of daily icv treatment with the DPIV- inhibitor isoleucyl thiazolidine fumarate over a wide range of dosages in female Lewis rats for 10 days with the treatment being conducted from day 5-15 post immunization with MBP in CFA.
  • This design was aimed at investigating the effects of the drug on the cellular components constituting the local inflammation within the CNS during EAE.
  • lev treatment with 5-50nmol dosages of isoleucyl thiazolidine fumarate caused a dose-dependent anti-inflammatory effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

The present invention provides a new use of DPIV-inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in treating conditions mediated by DPIV or DPIV-Iike enzymes, such as immune, autoimmune or central nervous system disorder selected from the group consisting of strokes, tumors, ischemia, Parkinson's disease and migraines. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of multiple sclerosis.

Description

New Use Of Dipeptidyl Peptidase IV Inhibitors
Field Of The Invention
The present invention relates to inhibitors of dipeptidyl peptidase IV and dipeptidyl peptidase IV-like enzyme activity and, more particularly, pharmaceutical compositions containing said compounds, and the use of said compounds for the treatment of central nervous disorders, immune and autoimmune disorders. The present invention especially provides a method for the treatment of multiple sclerosis.
Background Art
Dipeptidyl peptidase IV (DPIV) is a serine protease which cleaves N-terminal dipeptides from a peptide chain containing, preferably, a proline residue in the penultimate position. Although the biological role of DPIV in mammalian systems has not been completely established, it is believed to play an important role in neuropeptide metabolism, T-cell activation, and the entry of HIV into lymphoid cells.
Likewise, it has been discovered that DPIV is responsible for inactivating glucagon-like peptide-1 (GLP-1 ) and glucose-dependent insulinotropic peptide also known as gastric-inhibitory peptide (GIP). Since GLP-1 is a major stimulator of pancreatic insulin secretion and has direct beneficial effects on glucose disposal, in WO 97/40832 and US 6,303,661 inhibition of DPIV and DPIV-like enzyme activity was shown to represent an attractive approach for treating non-insulin-dependent diabetes meilitus (NIDD ).
The present invention provides a new use of DPIV-inhibitors for the prophylaxis and treatment of conditions mediated by inhibition of DPIV and DPIV-like enzymes, in particular the prophylaxis and treatment of neuronal disorders and immune disorders including multiple sclerosis, and pharmaceutical compositions e.g. useful in inhibiting DPIV and DPIV-like enzymes and a method of inhibiting said enzyme activity.
This invention relates to a method of treatment, in particular to a method for the prophylaxis and treatment of central nervous disorders, immune and autoimmune disorders, especially multiple sclerosis and to compounds and compositions for use in such method. Dipeptidyl peptidase IV (DPIV) is a post-pro|ine (to a lesser extent post- alanine, post-serine or post-glycine) cleaving serine protease found in various tissues of the body including kidney, liver, and intestine.
It is known that DPIV-lnhibitors may be useful for the treatment of impaired glucose tolerance and diabetes mellitus (International Patent Application, Publication Number WO 99/61431 , Pederson RA et al, Diabetes. 1998 Aug; 47(8):1253-8 and Pauly RP et al, Metabolism 1999 Mar; 48(3):385-9). In particular WO 99/61431 discloses DPIV-lnhibitors comprising an amino acid residue and a thiazolidine or pyrrolidine group, and salts thereof, especially L-tf7reo-isoleucyl thiazolidine, L-a//o- isoleucyl thiazolidine, L-fΛreo-isoleucyl pyrrolidine, L-a//o-isoleucyl thiazolidine, L-a//o- isoleucyl pyrrolidine, and salts thereof.
Further examples of low molecular weight dipeptidyl peptidase IV inhibitors are agents such as tetrahydroisoquinolin-3-carboxamide derivatives, N-substituted 2- cyanopyroles and -pyrrolidines, N-(N'-substituted glycyl)-2-cyanopyrrolidines, N- (substituted glycyl)-thiazoIidines, N-(substituted glycyl)-4-cyanothiazoϋdines, amino- acyl-borono-prolyl-inhibitors and cyclopropyl-fused pyrrolidines. Inhibitors of dipeptidyl peptidase IV are described in US 6,011 ,155; US 6,107,317; US 6,110,949; US 6,124,305; US 6,172,081 ; WO 99/61431 , WO 99/67278, WO 99/67279, DE 198 34 591 , WO 97/40832, DE 196 16 486 C 2, WO 98/19998, WO 00/07617, WO 99/38501, WO 99/46272, WO 99/38501 , WO 01/68603, WO 01/40180, WO 01/81337, WO 01/81304, WO 01/55105, WO 02/02560 and WO 02/14271 , the teachings of which are herein incorporated by reference in their entirety concerning these inhibitors, their uses, definition and their production. The term DPIV-like enzymes relates to structurally and/or functionally DPIV/CD26-related enzyme proteins (Sedo & Malik, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta 2001 , 36506: 1-10). In essence, this small group of enzymes has evolved during evolution to release H-Xaa-Pro-Dipeptides and H-Xaa-Ala-Dipeptides from N-terminus of oligo- or polypeptides. They show the common feature, that they accomotate in the Pro-position also Al, Ser, Thr and other amino acids with small hydrophobic side- chains as, Gly or Val. The hydrolytic efficacy is ranked Pro>Ala» Ser, Thr » Gly, Val. Same proteins have been only available in such small quantities, that only the post- Pro or post-Ala cleavage could be established. While the proteins: DPIV, DP II, FAP (Seprase), DP 6, DP 8 and DP 9 are structurally related and show a high sequence homology of , attraction is an extraordinary functional DPIV-like enzyme, characterized by a similar activity and inhibitory pattern.
Further DPIV-like enzymes are disclosed in WO 01/19866, WO 02/34900 and WO02/31134. WO 01/19866 discloses novel human dipeptidyl aminopeptidase 8 (DPP8) with structural und functional similarities to DPIV and fibroblast activation protein (FAP). WO 02/34900 discloses a novel dipeptidyl peptidase 9 (DPP9) with significant homology to the amino acid sequences of DPIV and DPP8. WO 02/31134 discloses three DPIV-like enzymes, DPRP1 , DPRP2 and DPRP3. Sequence analysis revealed, that DPRP1 is identical to DPP8, as disclosed in WO 01/19866, that DPRP2 is identical to DPP9 and that DPRP3 is identical to KIAA1492 as disclosed in WO 02/04610.
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with a presumed autoimmune pathogenesis involving autoantigen-specific CD4+ T cells and cytokines (Rohowsky-Kochan, C, Molinaro, D, and Cook, SD. Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis. Multiple Sclerosis 6, 69-77. 2001.). The degeneration underlying MS results from degradation of the myelin sheath, an electrically insulating fatty layer that surrounds nerve fibers and permits the rapid conduction of electrical signals. This loss of myelin can seriously impair the ability of neurons to conduct an electrical signal effectively. Symptoms will depend on where in the central nervous system (CNS) the myelin loss occurs and, thus, which nerve pathways become impaired.
The disease appears to be autoimmune in nature, i.e., the body's own immune system is responsible for the damage. The principal target of the autoimmune reaction appears to be Myelin Basic Protein (MBP), although other MS antigens have been proposed. In the early stages of the disease, a type of CNS cell called an oligodendrocyte can repair this damage and replace the lost myelin. However, these cells can also be destroyed in MS and so sufferers may lose the ability to repair the damage over time, which allows the disease to progress.
The mechanism of disease progression appears complex and several components of the immune system have been linked to the disease. While the underlying tissue damage appears to result predominantly from a T cell mediated response, antibodies against MS antigens are often present in the cerebrospinal fluid (CSF) and at active lesions. Antibodies are not normally present in the CSF and some disruption of the blood brain barrier (BBB), a protective membrane around the CNS, must also occur to allow antibodies, T cells and macrophages to enter the CSF. This change in the permeability of the BBB appears to be one of the defining events in the development of MS.
Activated macrophages secrete pro-inflammatory cytokines such as TNF-α and interferon-γ, leading to the production of destructive enzymes and free radicals. In addition to the complex nature of the immune response itself, the disease can also affect a number of targets. As well as the myelin sheath, other cells such as astrocytes and microglia can be attacked, forming discreet regions of damage known as plaques or lesions. The lesions are also known as scleroses (hence the name) and can occur in both the brain and the spinal cord. The sites of the lesions tend to be near blood vessels and are commonly found on the optic nerve, cerebellum, periventricular regions and spinal cord.
The initial mechanism for the onset of disease remains largely unknown and the number of active lesions at any given time is actually quite low. The heterogeneous nature of the disease and the number of clinical subtypes that this creates suggest that MS is probably a series of related conditions rather than one disease.
Summary Of The Invention
The present invention provides a new use of DPIV-inhibitors. The compounds of formulas 1 to 12, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in treating conditions mediated by DPIV or DPIV-like enzymes, such as immune, autoimmune or central nervous system disorders selected from the group consisting of strokes, tumors, ischemia, Parkinson's disease, and migraines. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of multiple sclerosis.
Brief Description Of The Drawings
Figure 1 : Illustrates the clinical course of experimental autoimmune encephalomyelitis (EAE). The effects of different dosages of isoleucyl thiazolidine fumarate on the clinical course of EAE in adult female Lewis rats were studied. Symbols represent means ± SEM of the mean clinical score per day. Two factor ANOVA for repeated measures revealed a significant interaction between the factors "treatment" "clinical score over time" indicating that during the initial acute phase of the disease between day 9-12(13), the DPIV inhibitors aggravated the disease while during between day 13-15 they improved or accelerated recovery from disease.
Figure 2: Illustrates the clinical course of experimental autoimmune encephalomyelitis (EAE) in isoleucyl thiazolidine fumarate treated rats split by days 10-15 post immunization. Separate one factor ANOVAs revealed significant disease-aggravating effect at the 1 mg dosage on day 11 and 12 p.i., while the 10mg dose significantly reduced clinical score at day 15 p.i. This indicates that the inhibitor initially tends to aggravate the disease while at later stages it results in an accelerated recovery from disease. Columns represent means ± SEM of the mean clinical score per day. Asterisks indicate significant post-hoc effects in the PLSD test with *<0.05 and **<0.001.
Figure 3: Illustrates the clinical course of experimental autoimmune encephalomyelitis (EAE). The effects of different dosages of isoleucyl thiazolidine fumarate during ongoing disease (days 5-15 p.i.) on the clinical course of EAE in adult male Lewis rats were studied. Symbols represent means ± SEM of the mean clinical score per day. Two factor ANOVA for repeated measures revealed significant main effects for the factor treatment and a significant interaction between the factors "treatment" and "clinical score over time" indicating that treatment significantly modulated the course of the disease and furthermore indicating that the different dosage act differentially. After initiation of treatment moderate dosages act proinflammatory and cause an "early peak" or aggravation of disease. During the acute phase of the disease between day 9-13, high dose of isoleucyl thiazolidine fumarate clearly improved the clinical course
Figure 4: Illustrates the clinical course of experimental autoimmune encephalomyelitis (EAE) in isoleucyl thiazolidine fumarate treated rats split by days 10-15 post immunization. Separate one factor ANOVAs revealed significant disease-aggravating effect at the 1 mg dosage on day 11 and 12 p.i., while the 10mg dose significantly reduced clinical score at day 15 p.i. This indicates that the inhibitor initially tends to aggravate the disease while at later stages it results in an accelerated recovery from disease. Columns represent means ± SEM of the mean clinical score per day. Asterisks indicate significant post-hoc effects in the PLSD test with *<0.05 and **<0.001.
Figure 5: Illustrates the clinical course of experimental autoimmune encephalomyelitis (EAE). The effects of different dosages of isoleucyl thiazolidine fumarate injected icv during ongoing disease (days 5-15 p.i.) on the clinical course of EAE in adult female Lewis rats were studied. Symbols represent means ± SEM of the mean clinical score per day and group. Two factor ANOVA for repeated measures revealed significant main effects for the factor treatment and a significant interaction between the factors "treatment" x "clinical score over time" indicating that treatment significantly modulated the course of the disease. All dosages of the DPIV-inhibitor exhibited ant-inflammatory effects with a delay of onset and an improvement of the clinical course.
Detailed Description Of The Invention
The present invention relates to the area of dipeptidyl peptidase IV (DPIV) inhibition and, more particularly, to a new use of inhibitors of DPIV and DPIV-like enzyme activity for the prevention and treatment of neuronal and immune disorders, in particular for the treatment of multiple sclerosis, and pharmaceutical compositions containing said compounds.
In one illustrative embodiment, the present invention relates to dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof, referred to hereinafter as dipeptide compounds. Especially suitable for the purpose according to the invention are dipeptide compounds in which the amino acid is preferably selected from a natural amino acid, such as, for example, leucine, valine, glutamine, glutamic acid, proline, isoleucine, asparagines and aspartic acid.
The dipeptide compounds used according to the invention exhibit at a concentration (of dipeptide compounds) of 10 μM, indicated in Table 7, a reduction in the activity of dipeptidyl peptidase IV or DPIV-analogous enzyme activities of at least 10 %, especially of at least 40 %. Frequently a reduction in activity of at least 60 % or at least 70 % is also required. Preferred effectors may also exhibit a reduction in activity of a maximum of 20 % or 30 %.
Preferred compounds are L-a//o-isoleucyl thiazolidine, L-#7reo-isoleucyl pyrrolidine and salts thereof, especially the fumaric salts, and L-a//o-isoleucyl pyrrolidine and salts thereof. Especially preferred compounds are glutaminyl pyrrolidine and glutaminyl thiazolidine of formulas 1 and 2:
Figure imgf000009_0001
(1)
Figure imgf000010_0001
(2)
Further preferred compounds are given in Table 1.
The salts of the dipeptide compounds can be present in a molar ratio of dipeptide (- analogous) component to salt component of 1 : 1 or 2 : 1. Such a salt is, for example, (lle-Thia)2 fumaric acid.
Table 1 : Structures of further preferred dipeptide compounds
Effector
H-Asn-pyrrolidine
H-Asn-thiazolidine
H-Asp-pyrrolidine
H-Asp-thiazolidine
H-Asp(NHOH)-pyrrolidine H-Asp(NHOH)-thiazolidine
H-Glu-pyrrolidine
H-GIu-thiazolidine
H-Glu(NHOH)-pyrrolidine
H-Glu(NHOH)-thiazolidine H-His-pyrrolidine
H-His-thiazolidine
H-Pro-pyrrolidine
H-Pro-thiazolidine
H-lle-azididine
H-lle-pyrrolidine H-L-allo-lle-thiazolidine
H-Val-pyrrolidine
H-Val-thiazolidine
In another preferred embodiment, the present invention provides peptide compounds of formula 3 useful for competitive modulation of dipeptidyl peptidase IV catalysis:
K C E
( 3 ) wherein
A, B, C, D and E are independently any amino acid moieties including proteinogenic amino acids, non-proteinogenic amino acids, L-amino acids and D- amino acids and wherein E and/or D may be absent with additional conditions as hereinafter detailed:
Further conditions regarding formula (3):
A is any amino acid except a D-amino acid;
B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxyiic acid and pipecolic acid,
C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine,
D is any amino acid or missing, and
E is any amino acid or missing
or C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid, except N-alkylated amino acids, e.g. N-methyl valine and sarcosine and except a D- amino acid,
D is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid and pipecolic acid, and
E is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine.
Examples of amino acids throughout the claims and the description are: aspartic acid (Asp), glutamic acid (Glu), arginine (Arg), lysine (Lys), histidine (His), glycine (Gly), serine (Ser) and cysteine (Cys), threonine (Thr), asparagine (Asn), glutamine (Gin), tyrosine (Tyr), alanine (Ala), proline (Pro), valine (Val), isoleucine (lie), leucine (Leu), methionine (Met), phenylalanine (Phe), tryptophan (Trp), hydroxyproline (Hyp), beta-alanine (beta-Ala), 2-amino octanoic acid (Aoa), azetidine- (2)-carboxylic acid (Ace), pipecolic acid (Pip), 3-amino propionic, 4-amino butyric and so forth, alpha-aminoisobutyric acid (Aib), sarcosine (Sar), ornithine (Orn), citrulline (Cit), homoarginine (Har), t-butylalanine (.--butyl-Ala), t-butylglycine (f-butyl-Gly), N- methylisoleucine (N-Melle), phenylglycine (Phg), cyclohexylalanine (Cha), norleucine (Nle), cysteic acid (Cya) and methionine sulfoxide (MSO), Acetyl-Lys, modified amino acids such as phosphoryl-serine (Ser(P)), benzyl-serine (Ser(Bzl)) and phosphoryl- tyrosine (Tyr(P)), 2-aminobutyric acid (Abu), aminoethylcysteine (AECys), carboxymethylcysteine (Cmc), dehydroalanine (Dha), dehydroamino-2-butyric acid (Dhb), carboxyglutaminic acid (Gla), homoserine (Hse), hydroxylysine (Hyl), cis- hydroxyproline (c/sHyp), fr-ans-hydroxyproline (transHyp), isovaline (Iva), pyroglutamic acid (Pyr), norvaline (Nva), 2-aminobenzoic acid (2-Abz), 3- aminobenzoic acid (3- Abz), 4- aminobenzoic acid (4-Abz), 4-(aminomethyl)benzoic acid (Amb), 4- (aminomethyl)cyclohexanecarboxylic acid (4-Amc), Penicillamine (Pen), 2-Amino-4- cyanobutyric acid (Cba), cycloalkane-carboxylic aicds. Examples of tσ-amino acids are e.g.: 5-Ara (aminoraleric acid), 6-Ahx (aminohexanoic acid), 8-Aoc (aminooctanoic aicd), 9-Anc (aminovanoic aicd), 10-Adc (aminodecanoic acid), 11-Aun (aminoundecanoic acid), 12-Ado (aminododecanoic acid). Further amino acids are: indanylglycine (Igl), indoline-2-carboxylic acid (Idc), octahydroindole-2-carboxylic acid (Oic), diaminopropionic acid (Dpr), diaminobutyric acid (Dbu), naphtylalanine (1-Nal), (2-Nal), 4-aminophenylaIanin (Phe(4-NH2)), 4- benzoylphenylalanine (Bpa), diphenylalanine (Dip), 4-bromophenylalanine (Phe(4- Br)), 2-chlorophenylalanine (Phe(2-CI)), 3-chlorophenylalanine (Phe(3-CI)), 4- chlorophenylalanine (Phe(4-CI)), 3,4-chlorophenylalanine (Phe (3,4-CI2)), 3- fluorophenylalanine (Phe(3-F)), 4- fluorophenylalanine (Phe(4-F)), 3,4- fluorophenylalanine (Phe(3,4-F2)), pentafluorophenylalanine (Phe(F5)), 4- guanidinophenylalanine (Phe(4-guanidino)), homophenylalanine (hPhe), 3- jodophenylalanine (Phe(3-J)), 4 jodophenylalanine (Phe(4-J)), 4-methylphenylalanine (Phe(4-Me)), 4-nitrophenylalanine (Phe-4-NO2)), biphenylalanine (Bip), 4- phosphonomehtylphenylalanine (Pmp), cyclohexyglycine (Ghg), 3-pyridinylalanine (3- Pal), 4-pyridinylalanine (4-Pal), 3,4-dehydroproline (A-Pro), 4-ketoproline (Pro(4- keto)), thioproline (Thz), isonipecotic acid (Inp), 1 ,2,3,4,-tetrahydroisoquinolin-3- carboxylic acid (Tic), propargylglycine (Pra), 6-hydroxynorleucine (NU(6-OH)), homotyrosine (hTyr), 3-jodotyrosine (Tyr(3-J)), 3,5-dijodotyrosine (Tyr(3,5-J2)), d- methyl-tyrosine (Tyr(Me)), 3-NO2-tyrosine (Tyr(3-NO2)), phosphotyrosine (Tyr(PO3H2)), alkylglycine, 1-aminoindane-1-carboxy acid, 2-aminoindane-2-carboxy acid (Aic), 4-amino-methylpyrrol-2-carboxylic acid (Py), 4-amino-pyrrolidine-2- carboxylic acid (Abpc), 2-aminotetraline-2-carboxylic acid (Ate), diaminoacetic acid (Gly(NH2)), diaminobutyric acid (Dab), 1 ,3-dihydro-2H-isoinole-carboxylic acid (Disc), homocylcohexylalanin (hCha), homophenylalanin (hPhe oder Hof), at7S-3-phenyl- azetidine-2-carboxylic acid, 4-phenyl-pyrrolidine-2-carboxylic acid, 5-phenyl- pyrrolidine-2-carboxylic acid, 3-pyridylalanine (3-Pya), 4-pyridylalanine (4-Pya), styrylalanine, tetrahydroisoquinoline-1 -carboxylic acid (Tiq), 1 ,2,3,4- tetrahydronorharmane-3-carboxylic acid (Tpi), β-(2-thienryl)-alanine (Tha) Other amino acid substitutions for those encoded in the genetic code can also be included in peptide compounds within the scope of the invention and can be classified within this general scheme.
Proteinogenic amino acids are defined as natural protein-derived α-amino acids. Non-proteinogenic amino acids are defined as all other amino acids, which are not building blocks of common natural proteins.
The resulting peptides may be synthesized as the free C-terminal acid or as the C- terminal amide form. The free acid peptides or the amides may be varied by side chain modifications. Such side chain modifications are for instance, but not restricted to, homoserine formation, pyroglutamic acid formation, disulphide bond formation, deamidation of asparagine or glutamine residues, methylation, t-butylation, t- butyloxycarbonylation, 4-methylbenzylation, thioanysilation, thiocresylation, bencyloxymethylation, 4-nitrophenylation, bencyloxycarbonylation, 2- nitrobencoylation, 2-nitrosulphenylation, 4-toluenesulphonylation, pentafluorophenylation, diphenylmethylation, 2-chlorobenzyloxycarbonylation, 2,4,5- trichlorophenylation, 2-bromobenzyloxycarbonylation, 9- fluorenylmethyloxycarbonylation, triphenylmethylation, 2,2,5,7,8,- pentamethylchroman-6-sulphonylation, hydroxylation, oxidation of methionine, formylation, acetylation, anisylation, bencylation, bencoylation, trifluoroacetylation, carboxylation of aspartic acid or glutamic acid, phosphorylation, sulphation, cysteinylation, glycolysation with pentoses, deoxyhexoses, hexosamines, hexoses or N-acetylhexosamines, famesylation, myristolysation, biotinylation, palmitoylation, stearoylation, geranylgeranylation, glutathionylation, 5'-adenosylation, ADP- ribosylation, modification with N-glycolylneuraminic acid, N-acetylneuraminic acid, py doxal phosphate, lipoic acid, 4'-phosphopantetheine, or N-hydroxysuccinimide. In the compounds of formula (3), the amino acid moieties A, B, C, D, and E are respectively attached to the adjacent moiety by amide bonds according to standard nomenclature so that the amino-terminus (N-terminus) of the amino acids (peptide) is drawn on the left and the carboxyl-terminus of the amino acid (peptide) is drawn on the right.
Until the present invention by Applicants, known peptide substrates of the proline- specific serine protease dipeptidyl peptidase IV in vitro are the tripeptides Diprotin A (lle-Pro-lle), Diprotin B (Val-Pro-Leu) and Diprotin C (Val-Pro-lle). Applicants have unexpectedly discovered that the compounds disclosed here act as substrates of dipeptidyl peptidase IV in vivo in a mammal and, in pharmacological doses, inhibit the physiological turnover of endogenous substrates by competitive catalysis.
Particularly preferred compounds of the present invention that are useful as modulators of dipeptidyl peptidase IV and DPIV - like enzymes include those compounds which show Kj-values for DPIV binding, effectively in DPIV inhibition in vivo after i.v. and/or p.o. administration to Wistar rats
Further preferred compounds which can be used according to the present invention are Peptidylketones of formula 4:
Figure imgf000015_0001
wherein
A is selected from
Figure imgf000016_0001
X1 is H or an acyl or oxycarbonyl group incl. all amino acids and peptide residues, X2 is H, -(CH)n-NH-C5H3N-Y with n=2-4 or C5H3N-Y (a divalent pyridyl residue) and Y is selected from H, Br, Cl, I, NO2 or CN, X3 is H or a phenyl or pyridyl residue, unsubstituted or substituted with one, two or more alkyl, alkoxy, halogen, nitro, cyano or carboxy residues, X4 is H or a phenyl or pyridyl residue, unsubstituted or substituted with one, two or more alkyl, alkoxy, halogen, nitro, cyano or carboxy residues, X5 is H or an alkyl, alkoxy or phenyl residue, X6 is H or an alkyl residue.
for n = 1
X is selected from: H, OR2, SR2, NR2R3, N+R2R3R4, wherein:
R2 stands for acyl residues, which are unsubstituted or substituted with one, two or more alkyl, cycloalkyl, aryl or heteroaryl residues, or for all amino acids and peptidic residues, or alkyl residues, which are unsubstituted or substituted with one, two or more alkyl, cycloalkyl, aryl and heteroaryl residues,
R3 stands for alkyl and acyl functions, wherein R2 and R3 may be part of one or more ring structures of saturated and unsaturated carbocyclic or heterocyclic structures,
R4 stands for alkyl residues, wherein R2 and R4 or R3 and R4 may be part of one or more ring structures of saturated and unsaturated carbocyclic or heterocyclic structures,
for n = 0 X is selected from:
Figure imgf000017_0001
wherein B stands for: O, S, NR5, wherein R5 is H, an alkyliden or acyl,
C, D, E, F, G, H are independently selected from unsubstituted and substituted alkyl, oxyalkyl, thioalkyl, aminoalkyl, carbonylalkyl, acyl, carbamoyl, aryl and heteroaryl residues; and
for n= 0 and n=1
Z is selected from H, or a branched or single chain alkyl residue from C1-C9 or a branched or single chain alkenyl residue from C2-C9, a cycloalkyl residue from C3-C8, a cycloalkenyl residue from Cs-C , an aryl- or heteroaryl residue, or a side chain selected from all side chains of all natural amino acids or derivatives thereof.
Further, according to the present invention compounds of formulas 5, 6, 7,8, 9, 10 and 11 , including all stereoisomers and pharmaceutical acceptable salts thereof are disclosed and can be used
(5)
Figure imgf000017_0002
Figure imgf000018_0001
Figure imgf000018_0002
wherein:
R1 is H, a branched or linear C1-C9 alkyl residue, a branched or linear C2-C9 alkenyl residue, a C3-Cs cycloalkyl- , Cs-C cycloalkenyl-, aryl- or heteroaryl residue or a side chain of a natural amino acid or a derivative thereof,
R3 and R4 are independently selected from H, hydroxy, alkyl, alkoxy, aryloxy, nitro, cyano or halogen,
A is H or an isoster of a carbonic acid, like a functional group selected from CN, SO3H, CONHOH, PO3R5R6, tetrazole, amide, ester, anhydride, thiazole and imidazole,
B is selected from:
Figure imgf000018_0003
wherein :
R5 is H, -(CH)n-NH-C5H3N-Y with n=2-4 and C5H3N-Y (a divalent pyridyl residue) with
Y = H, Br, Cl, I, NO2 or CN ,
R10 is H, an acyl, oxycarbonyl or a amino acid residue ,
W is H or a phenyl or pyridyl residue, unsubstituted or substituted with one, two or more alkyl, alkoxy, halogen, nitro, cyano or carboxy residues,
W1 is H, an alkyl, alkoxy or phenyl residue,
Z is H or a phenyl or pyridyl residue, unsubstituted or substituted with one, two or more alkyl, alkoxy, halogen, nitro, cyano or carboxy residues,
Z1 is H or an alkyl residue,
D is a cyclic C -C alkyl, C4-C alkenyl residue which can be unsubstituted or substituted with one, two or more alkyl groups or a cyclic 4-7-membered heteroalkyl or a cyclic 4-7-membered heteroalkenyl residue,
X2 is O, NR6, N+(R7)2, or S,
X3 to X12 are independently selected from CH2, CR8R9, NR6, N+(R7)2, O, S, SO and SO2, including all saturated and unsaturated structures,
R6, R7, R8, R9 are independently selected from H, a branched or linear CrCg alkyl residue, a branched or linear C2-C9 alkenyl residue, a C3-C8 cycloalkyl residue, a C5- C7 cycloalkenyl residue, an aryl or heteroaryl residue, with the following provisions:
Formula 6: X6 is CH if A is not H, Formula 7: X10 is C if A is not H, Formula 8: X7 is CH if A is not H, Formula 9: X12 is C if A is not H.
Throughout the description and the claims the expression "acyl" can denote a C-ι-20 acyl residue, preferably a C-t-β acyl residue and especially preferred a Cι-4 acyl residue, "cycloalkyl" can denote a C3-12 cycloalkyl residue, preferably a C , C5 or Cβ cycloalkyl residue, "carbocyclic" can denote a C3-12 carbocyclic residue, preferably a C4, C5 or Cβ carbocyclic residue. "Heteroaryl" is defined as an aryl residue, wherein 1 to 4, preferably 1 , 2 or 3 ring atoms are replaced by heteroatoms like N, S or O. "Heterocyclic" is defined as a cycloalkyl residue, wherein 1, 2 or 3 ring atoms are replaced by heteroatoms like N, S or O. "Peptides" are selected from dipeptides to decapeptides, preferred are dipeptides, tripeptides, tetrapeptides and pentapeptides. The amino acids for the formation of the "peptides" can be selected from the those listed above.
Because of the wide distribution of the protein in the body and the wide variety of mechanisms involving DPIV, DPIV activity and DPIV-related proteins, systemic therapy (enteral or parenteral administration) with DPIV-inhibitors can result in a series of undesirable side-effects.
The problem to be solved was, moreover, to provide compounds that can be used for targeted influencing of locally limited pathophysiological and physiological processes. The problem of the invention especially consists in obtaining locally limited inhibition of DPIV or DPIV-analogous activity for the purpose of targeted intervention in the regulation of the activity of locally active substrates. This problem is solved according to the invention by compounds of the general formula (12)
A-
B (12)
wherein
A is an amino acid having at least one functional group in the side chain,
B is a chemical compound covalently bound to at least one functional group of the side chain of A,
C is a thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine group amide-bonded to A.
The compounds can be used for reducing immune, autoimmune or central nervous system related disorders.
In accordance with a preferred embodiment of the invention, pharmaceutical compositions are used comprising at least one compound of the general formula (12) and at least one customary adjuvant appropriate for the site of action.
Preferably A is an α-amino acid, especially a natural α-amino acid having one, two or more functional groups in the side chain, preferably threonine, tyrosine, serine, arginine, lysine, aspartic acid, glutamic acid or cysteine.
Preferably B is an oligopeptide having a chain length of up to 20 amino acids, a polyethylene glycol having a molar mass of up to 20 000 g/mol, an . optionally substituted organic amine, amide, alcohol, acid or aromatic compound having from 8 to 50 C atoms.
Throughout the description and the claims the expression "alkyl" can denote a Cι_5o alkyl group, preferably a C6-3o alkyl group, especially a C8-12 alkyl group; for example, an alkyl group may be a methyl, ethyl, propyl, isopropyl or butyl group. The expression "alk", for example in the expression "alkoxy", and the expression "alkan", for example in the expression "alkanoyl", are defined as for "alkyl"; aromatic compounds are preferably substituted or optionally unsubstituted phenyl, benzyl, naphthyl, biphenyl or anthracene groups, which preferably have at least 8 C atoms; the expression "alkenyl" can denote a C2-10 alkenyl group, preferably a C2-6 alkenyl group, which has the double bond(s) at any desired location and may be substituted or unsubstituted; the expression "alkynyl" can denote a C2-ιo alkynyl group, preferably a C2-6 alkynyl group, which has the triple bond(s) at any desired location and may be substituted or unsubstituted; the expression "substituted" or substituent can denote any desired substitution by one or more, preferably one or two, alkyl, alkenyl, alkynyl, mono- or multi-valent acyl, alkanoyl, alkoxyalkanoyl or alkoxyalkyl groups; the aforementioned substituents may in turn have one or more (but preferably zero) alkyl, alkenyl, alkynyl, mono- or multi-valent acyl, alkanoyl, alkoxyalkanoyl or alkoxyalkyl groups as side groups; organic amines, amides, alcohols or acids, each having from 8 to 50 C atoms, preferably from 10 to 20 C atoms, can have the formulae (alkyl)2N- or alkyl-NH-, -CO-N(alkyl)2 or -CO-NH(alkyl), -alkyl-OH or -alkyl-COOH.
Despite an extended side chain function, the compounds of formula (12) can still bind to the active centre of the enzyme dipeptidyl peptidase IV and analogous enzymes but are no longer actively transported by the peptide transporter PepT1. The resulting reduced or greatly restricted transportability of the compounds according to the invention leads, in ideal manner, to local or site directed inhibition of DPIV and DPIV-like enzyme activity. The compounds of formula (12) or the other compounds used in accordance with the invention can be present or used, respectively, in the form of racemates or in the form of enantiomerically pure compounds, preferably in the L-threo or L-allo form with respect to part A of formula (12).
By extending/expanding the side chain modifications, for example beyond a number of seven carbon atoms, it is accordingly possible to obtain a dramatic reduction in transportability (see Example 12). The Examples in Table 12.1 clearly show that, with increasing spatial size of the side chains, there is a reduction in the transportability of the substances. By spatially and sterically expanding the side chains, for example beyond the atom group size of a monosubstituted phenyl radical, hydroxylamine radical or amino acid residue, it is possible according to the invention to modify or suppress the transportability of the target substances.
According to the present invention, the compounds of formula (12) inhibit DPIV or DPIV-like enzyme activity in the body of a mammal in a site specific manner. It is accordingly possible to influence local physiological and pathophysiological conditions (inflammation, psoriasis, arthritis, immune, autoimmune diseases, allergies, but also central nervous system related disorders) effectively and with dramatically reduced side-effects.
Preferred compounds of formula (12) are compounds, wherein the oligopeptides have chain lengths of from 3 to 15, especially from 4 to 10, amino acids, and/or the polyethylene glycols have molar masses of at least 250 g/mol, preferably of at least 1500 g/mol and up to 15 000 g/mol, and/or the optionally substituted organic amines, amides, alcohols, acids or aromatic compounds have at least 12 C atoms and preferably up to 30 C atoms.
The compounds of the present invention can be converted into and used as acid addition salts, especially pharmaceutically acceptable acid addition salts. The pharmaceutically acceptable salt generally takes a form in which an amino acids basic side chain is protonated with an inorganic or organic acid. Representative organic or inorganic acids include hydrochloric, hydrobromic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toulenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. All pharmaceutically acceptable acid addition salt forms of the compounds of formulas 1 and 12 are intended to be embraced by the scope of this invention.
In view of the close relationship between the free compounds and the compounds in the form of their salts, whenever a compound is referred to in this context, a corresponding salt is also intended, provided such is possible or appropriate under the circumstances.
The present invention further includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the desired therapeutically active compound. Thus, in these cases, the use of the present invention shall encompass the treatment of the various disorders described with prodrug versions of one or more of the claimed compounds, which convert to the above specified compound in vivo after administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985 and the patent applications DE 198 28 113 and DE 19828 114, which are fully incorporated herein by reference.
Where the compounds or prodrugs according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds or prodrugs possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms of the compounds or prodrugs may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e. hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
The compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
As indicated above, the compounds and prodrugs of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in inhibiting DPIV and DPIV - like enzyme activity. The ability of the compounds and prodrugs of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms to inhibit DPIV and DPIV - like enzyme activity may be demonstrated employing the DPIV activity assay for determination of the K\- values and the ICso-values in vitro, as described in examples 7 and 8.
The ability of the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms to inhibit DPIV in vivo may be demonstrated by oral or intravasal administration to Wistar rats, as described in example 11. The compounds of the present invention inhibit DPIV activity in vivo after both, oral and intravasal administration to Wistar rats.
DPIV is present in a wide variety of mammalian organs and tissues e.g. the intestinal brush-border (Gutschmidt S. et al., "In situ" - measurements of protein contents in the brush border region along rat jejunal villi and their correlations with four enzyme activities. Histochemistry 1981 , 72 (3), 467-79), exocrine epithelia, hepatocytes, renal tubuli, endothelia, myofibroblasts (Feller A.C. et al., A monoclonal antibody detecting dipeptidylpeptidase IV in human tissue. Virchows Arch. A. Pathol. Anat. Histopathol. 1986; 409 (2):263-73), nerve cells, lateral membranes of certain surface epithelia, e.g. Fallopian tube, uterus and vesicular gland, in the luminal cytoplasm of e.g., vesicular gland epithelium, and in mucous cells of Brunner's gland (Hartel S. et al., Dipeptidyl peptidase (DPP) IV in rat organs. Comparison of immunohistochemistry and activity histochemistry. Histochemistry 1988; 89 (2): 151- 61), reproductive organs, e.g. cauda epididymis and ampulla, seminal vesicles and their secretions (Agrawal & Vanha-Perttula, Dipeptidyl peptidases in bovine reproductive organs and secretions. Int. J. Androl. 1986, 9 (6): 435-52). In human serum, two molecular forms of dipeptidyl peptidase are present (Krepela E. et al., Demonstration of two molecular forms of dipeptidyl peptidase IV in normal human serum. Physiol. Bohemoslov. 1983, 32 (6): 486-96). The serum high molecular weight form of DPIV is expressed on the surface of activated T cells (Duke-Cohan J.S. et al., Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J. Immunol. 1996, 156 (5): 1714-21).
The compounds and prodrugs of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms are able to inhibit DPIV in vivo. In one embodiment of the present invention, all molecular forms, homologues and epitopes of DPIV from all mammalian tissues and organs, also of those, which are undiscovered yet, are intended to be embraced by the scope of this invention.
Among the rare group of proline-specific proteases, DPIV was originally believed to be the only membrane-bound enzyme specific for proline as the penultimate residue at the amino-terminus of the polypeptide chain. However, other molecules, even structurally non-homologous with the DPIV but bearing corresponding enzyme activity, have been identified recently. DPIV-like enzymes, which are identified so far, are e.g. fibroblast activation protein α, dipeptidyl peptidase IV β, dipeptidyl aminopeptidase-like protein, N-acetylated α-linked acidic dipeptidase, quiescent cell proline dipeptidase, dipeptidyl peptidase II, attractin and dipeptidyl peptidase IV related protein (DPP 8), and are described in the review article by Sedo & Malik (Sedo & Malik, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta 2001 , 36506: 1-10). Further DPIV-like enzymes are disclosed in WO 01/19866, WO 02/34900 and WO02/31134. WO 01/19866 discloses novel human dipeptidyl aminopeptidase 8 (DPP8) with structural und functional similarities to DPIV and fibroblast activation protein (FAP). WO 02/34900 discloses a novel dipeptidyl peptidase 9 (DPP9) with significant homology to the amino acid sequences of DPIV and DPP8. WO 02/31134 discloses three DPIV-like enzymes, DPRP1 , DPRP2 and DPRP3.
In another preferred embodiment of the present invention, all molecular forms, homologues and epitopes of proteins comprising DPIV-like enzyme activity, from all mammalian tissues and organs, also of those, which are undiscovered yet, are intended to be embraced by the scope of this invention.
The ability of the compounds and prodrugs of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms to inhibit DPIV-like enzymes may be demonstrated employing an enzyme activity assay for determination of the Ki-values in vitro as described in example 9. The Kj-values of the compounds of the present invention against porcine dipeptidyl peptidase II were exemplary determined as Kj = 8.52*10"5 M ± 6.33*10"6 M for glutaminyl pyrrolidine and K| = 1.07*10"5 M ± 3.81 *10"7 M for glutaminyl thiazolidine.
In another embodiment, the compounds and prodrugs of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms have only low, if no inhibitory activity against non-DPIV and non-DPIV - like proline specific enzymes. As described in example 10, with glutaminyl thiazolidine and glutaminyl pyrrolidine exemplarily, no inhibition of dipeptidyl peptidase I and prolyl oligopeptidase was found. Against prolidase, both compounds showed a marked lower efficacy compared to DPIV. The IC 50-values against prolidase were determined as IC 50 > 3mM for glutaminyl thiazolidine and as IC 50 = 3.4*10"4M ± 5.63*10"5 for glutaminyl pyrrolidine.
In view of their ability to inhibit DPIV and DPIV - like enzyme activity, the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in treating conditions mediated by said enzyme activities. Based on the findings described in the examples of the present invention and in the literature, it can be shown that the compounds disclosed herein are useful in the treatment of conditions such as immune, autoimmune disorders or central nervous system disorders, selected from the group consisting of strokes, tumors, ischemia, Parkinson's disease, and migraines.
In a more preferred embodiment, the compounds and prodrugs of this invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful for the treatment of multiple sclerosis. The ability of the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, to alleviate the signs of multiple sclerosis can be determined employing the EAE rat model. The method is described in example 13.
The present invention therefore provides a method of preventing or treating a condition mediated by modulation of the DPIV or DPIV - like enzyme activity in a subject in need thereof which comprises administering any of the compounds of the present invention or pharmaceutical compositions thereof in a quantity and dosing regimen therapeutically effective to treat the condition. Additionally, the present invention includes the use of the compounds and progdrugs of this invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for the preparation of a medicament for the prevention or treatment of a condition mediated by modulation of the DPIV activity in a subject. The compound may be administered to a patient by any conventional route of administration, including, but not limited to, intravenous, oral, subcutaneous, intramuscular, intradermal, parenteral and combinations thereof.
In an further illustrative embodiment, the present invention provides formulations for the compounds of formulas 1 to 12, and their corresponding pharmaceutically acceptable prodrugs and acid addition salt forms, in pharmaceutical compositions.
The term "subject" as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
As used herein, the term "composition" is intended to encompass a product comprising the claimed compounds in the therapeutically effective amounts, as well as any product which results, directly or indirectly, from combinations of the claimed compounds.
To prepare the pharmaceutical compositions used in this invention, one or more compounds of formulas 1 to 12, or their corresponding pharmaceutically acceptable acid addition salt forms, as the active ingredient, is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives may advantageously include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included.
Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.01 mg to about 1000 mg (preferably about 5 to about 500 mg) and may be given at a dosage of from about 0.1 to about 300 mg/kg bodyweight per day (preferably 1 to 50 mg/kg/day). The dosages, however, may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed. Typically the dosage will be regulated by the physician based on the characteristics of the patient, his/her condition and the therapeutic effect desired. Preferably these compositions are in unit dosage forms from such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is ideally mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is ideally dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules. This solid preformulation composition may then be subdivided into unit dosage forms of the type described above containing from about 0.01 to about 1000 mg, preferably from about 5 to about 500 mg of the active ingredient of the present invention.
The tablets or pills of the novel composition can be advantageously coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
This liquid forms in which the novel compositions of the present invention may be advantageously incorporated for administration orally or by injection include, aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.
Where the processes for the preparation of the compounds according to the invention give rise to a mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their components enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis. John Wiley & Sons, 1991 , fully incorporated herein by reference. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
The method of treating conditions modulated by dipeptidyl peptidase IV and DPIV - like enzymes described in the present invention may also be carried out using a pharmaceutical composition comprising one or more of the compounds as defined herein and a pharmaceutically acceptable carrier. The pharmaceutical composition may contain from about 0.01 mg to about 1000 mg, preferably about 5 to about 500 mg, of the compound(s), and may be constituted into any form suitable for the mode of administration selected. Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings. Compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixirs, emulsions, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions and suspensions.
Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen and dosage strength will need to be accordingly modified to obtain the desired therapeutic effects. More preferably, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders; lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or betalactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and other compounds known within the art.
The liquid forms are suitable in flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
The compound of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines using processes well described in the art.
Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamide-phenol, or polyethyl eneoxidepolyllysine substituted with palmitoyl residue. Furthermore, compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polyactic acid, polyepsilon caprolactone, polyhydroxy butyeric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
Compounds of this invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever treatment of the addressed disorders is required.
The daily dosage of the products may be varied over a wide range from 0.01 to 1.000 mg per adult human per day. For oral administration, the compositions are preferably provided in the form of tablets containing, 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250, 500 and 1000 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.1 mg/kg to about 300 mg/kg of body weight per day. Preferably, the range is from about 1 to about 50 mg/kg of body weight per day. The compounds may be administered on a regimen of 1 to 4 times per day.
Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, bioavailability due to the mode of administration, and the advancement of disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, should generally be considered in adjusting dosages.
The compounds or compositions of the present invention may be taken before a meal, while taking a meal or after a meal.
Examples
Example 1: Synthesis Of Dipeptide Compounds 1.1 General synthesis of isoleucyl thiazolidine salt
The Boc-protected amino acid BOC-lle-OH is placed in ethyl acetate and the batch is cooled to about - 5°C. N-Methylmorpholine is added dropwise, pivalic acid chloride (on a laboratory scale) or neohexanoyl chloride (on a pilot-plant scale) is added dropwise at constant temperature. The reaction is stirred for a few minutes for activation. N-Methylmorpholine (laboratory scale) and thiazolidine hydrochloride (laboratory scale) are added dropwise in succession, thiazolidine (pilot-plant scale) is added. Working-up in the laboratory is effected in conventional manner using salt solutions, on a pilot-plant scale the batch is purified with NaOH and CH3COOH solutions.
The removal of the BOC protecting group is carried out using HCI/dioxane (laboratory scale) or H2SO (pilot-plant scale). In the laboratory the hydrochloride is crystallised from EtOH/ether.
On a pilot-plant scale the free amine is prepared by the addition of NaOH/NH3. Fumaric acid is dissolved in hot ethanol, the free amine is added dropwise, and (lle- Thia)2 furmarate (M = 520.71 gmol"1) precipitates. The analysis of isomers and enantiomers is carried out by electrophoresis.
1.2 Synthesis of glutaminyl pyrrolidine free base
Acylation:
N-Benzyl-oxycarbonylglutamine (2.02 g, 7.21 mmol) was dissolved in 35 ml THF and brought to -15°C. Into that mixture CAIBE (isobutylchloroformiate) (0.937 ml, 7.21 mmol) and 4-methylmorpholine (0.795 ml, 7.21 mmol) where added and the solution was stirred for 15 min. The formation of the mixed anhydride was checked by TLC (eluent: CHCI3/MeOH: 9/1). After warming to -10°C pyrrolidine (0.596 ml, 7.21 mmol) was added. The mixture was brought to room temperature and stirred overnight.
Workup:
The sediment formed was filtered off and the solvent was evaporated. The resulting oil was taken up in ethylacetate (20 ml) and washed with a saturated solution of sodiumhydrogensulfate followed by a saturated solution of sodiumbicarbonate, water and brine. The organic layer was separated, dried and evaporated. The resulting product was checked for purity by TLC (eluent: CHCIs/MeOH: 9/1 ) Yield: 1.18 g, waxy solid
Cleavage:
1.18 g of the resulting solid Z-protected compound was dissolved in 40 ml absolute ethanol. Into the solution ca. 20 mg Pd on charcoal (10%, FLUKA) was added and the suspension was shaken under a hydrogen atmosphere for 3h. The progress of the reaction was monitored by TLC (eluent: CHCIs/MeOH: 9/1). After completion of the reaction the was removed to provide the free base. Yield: 99%
The purity was checked by means of TLC: n-butanole/AcOH/water/ethylacetate: 1/1/1/1 , Rf = 0.4. The identity of the reaction product was checked by NMR analysis.
1.3 Synthesis of glutaminyl thiazolidine hydrochloride
Acylation:
N-t-Butyl-oxycarbonylglutamine (2.0 g, 8.12 mmol) was dissolved in 5ml THF and brought to -15°C. Into that mixture CAIBE (isobutylchloroformiate) (1 ,06 ml, 8.12 mmol) and 4-methylmorpholine (0.895 ml, 8.12 mmol) where added and the solution was stirred for 15 min. The formation of the mixed anhydride was checked by TLC (eluent: CHCI3/MeOH: 9/1). After warming to -10°C another equivalent 4- methylmorpholine (0.895 ml, 8.12 mmol) and thiazolidine hydrochloride (1.02 g, 8.12 mmol) was added. The mixture was brought to room temperature and stirred overnight.
Workup:
The sediment formed was filtered off and the solvent was evaporated. The resulting oil was taken up in chloroform (20 ml) and washed with a saturated solution of sodiumhydrogensulfate followed by a saturated solution of sodiumbicarbonate, water and brine. The organic layer was separated, dried and evaporated. The resulting product was checked for purity by TLC (eluent: CHCl3/MeOH: 9/1 ) Yield: 1.64 g, solid
Cleavage:
640 mg of the resulting solid Boc-protected compound was dissolved in 3.1 ml ice cold HCI in dioxane (12.98 M, 20 equivalents) and left on ice. The progress of the reaction was monitored by TLC (eluent: CHCI3/MeOH: 9/1 ). After completion of the reaction the solvent was removed and the resulting oil was taken up in methanole and evaporated again. After that the resulting oil was dried over phosphorous-V-oxide and triturated two times with diethylether. The purity was checked by HPLC. Yield: 0.265 g
The purity was checked by HPLC. The identity of the reaction product was checked by NMR analysis.
1.4 Synthesis of Glutaminyl pyrrolidine hydrochloride
Acylation:
N-t-Butyl-oxycarbonylglutamine (3.0 g, 12.18 mmol) was dissolved in 7ml THF and brought to -15°C. Into that mixture CAIBE (isobutylchloroformiate) (1 ,6 ml, 12.18 mmol) and 4-methylmorpholine (1.3 ml, 12.18 mmol) where added and the solution was stirred for 15 min. The formation of the mixed anhydride was checked by TLC (eluent: CHCI3/MeOH: 9/1 ). After warming to -10°C 1 equivalent of pyrrolidjne (1.0 ml, 12.18 mmol) was added. The mixture was brought to room temperature and stirred overnight.
Workup:
The sediment formed was filtered off and the solvent was evaporated. The resulting oil was taken up in chloroform (20 ml) and washed with a saturated solution of sodiumhydrogensulfate followed by a saturated solution of sodiumbicarbonate, water and brine. The organic layer was separated, dried and evaporated. The resulting product was checked for purity by TLC (eluent: CHCI /MeOH: 9/1) Yield: 2.7 g solid
Cleavage:
2.7g of the resulting solid was dissolved in 13.0 ml ice cold HCI in dioxane (12.98 M, 20 equivalents) and left on ice. The progress of the reaction was monitored by TLC (eluent: CHCIs/MeOH: 9/1). After completion of the reaction the solvent was removed and the resulting oil was taken up in methanole and evaporated again. After that the resulting oil was dried over phosphorous-V-oxide and triturated two times with diethylether. Yield: 980 mg
The purity was checked by HPLC. The identity of the reaction product was checked by NMR analysis.
Example 2: Chemical characterization of selected dipeptide compounds
2.1 Melting point determination
Melting points were determined on a Kofler heating platform microscope from Leica Aktiengesellschaft, the values are not corrected, or on a DSC apparatus (Heumann-Pharma). 2.2 Optical rotation
The rotation values were recorded at different wavelengths on a "Polarimeter 341" or higher, from the Perkin-Elmer company.
2.3 Measurement conditions for the mass spectroscopy
The mass spectra were recorded by means of electrospray ionisation (ESI) on an "API 165" or API 365" from the PE Sciex company. The operation is carried out using an approximate concentration of c = 10 μg/ml, the substance is taken up in MeOH/H2O 50:50, 0.1 % HCO2H, the infusion is effected using a spray pump (20 μl/min). The measurement were made in positive mode [M+H]+, the ESI voltage is U=5600V.
2.4. Results
2.4.1 Tests on isoleucyl thiazolodine fumarate (isomer)
Figure imgf000040_0001
IT*F = isoleucyl thiazolidine fumarate
The NMR and HPLC data confirm the identity of the substance in question.
2.4.2 Tests on other isoleucyl thiazolidine salts
Figure imgf000040_0002
Example 3: Synthesis of Xaa-Pro-Yaa Tripeptides
All syntheses were carried out on a peptide synthesizer SP 650 (Labortec AG) applying Fmoc/tBu-strategy. Protected amino acids were purchased from Novabiochem or Bachem. trifluoro acetic acid (TFA) was purchased from Merck, triisopropyl silane (TIS) was purchased from Fluka.
Pre-loaded Fmoc-Yaa-Wang resin (2.8 g/ substitution level 0.57 mmol/g) was deprotected using 20% piperidine/ N,N-dimethylformamide (DMF). After washing with DMF a solution of 2 eq (1.1 g) of Fmoc-Pro-OH were solved in DMF (12ml solvent per gram resin). 2eq (1.04 g) of 2-(1 H-Benzotriazole 1-yl)-1 ,1 ,3,3-tetramethyluronium tetrafluoroborate (TBTU) and 4 eq (1.11 ml) of N,N-diisopropylethylamine (DIEA) were added and placed in the reaction vessel. The mixture was shaken at room temperature for 20 minutes. Then the coupling cycle was repeated. After subsequent washing with DMF, dichlormethane, isopropanol and diethyl ether the resulting Fmoc- Pro-lle-Wang resin was dried and then divided into 6 parts before coupling the last amino acid derivative.
Fmoc protecting group was removed as described above. After that 0.54 mmol of the Boc-amino acid, 0.54 mmol TBTU and 0.108 mmol DIEA in DMF were shaken for 20 min. The coupling cycle was repeated. Finally the peptide resin was washed and dried described above.
The peptide was cleaved from the resin using a mixture of trifluoroacetic acid (TFA) for 2.5 h, containing the following scavengers: TFA/H20/triisopropylsilane (TIS) = 9.5/0.25/0.25 The yields of crude peptides were 80-90% on the average. The crude peptide was purified by HPLC on a Nucleosil C18 column (7 μm, 250*21.20 mm, 100 A) using a linear gradient of 0.1% TFA/H2O with increasing concentration of 0.1% TFA/acetonitrile (from 5% to 65% in 40 min) at 6 ml/min.
The pure peptide was obtained by lyophilization, identified by Electrospray mass spectrometry and HPLC analysis.
sults - Identification of Xaa-Pro-Yaa tripeptides after chemical synthesis
Figure imgf000043_0001
1 [M+H+] were determined by Electrospray mass spectrometry in positive ionization mode.
2 RP-HPLC conditions: column: LiChrospher 100 RP 18 (5μm), 125 x 4 mm detection (UV): 214nm gradient system: acetonitrile (ACN)/H2O (0.1 % TFA) from 5% ACN to 50% in15 min, flow : 1 ml/min
k' = (trto)/to to = 1.16 min
^-butyl-Gly is defined as:
H5 OOH
Figure imgf000044_0001
Ser (P) and Ser (Bzl) are defined as phosphorylserine and benzylserine. Tyr (P) is defined as phosporyltyrosine.
Example 4: Synthesis of peptidylketones
Figure imgf000045_0001
8: R = 0C(O)Ac 6: R = OC(0)Ac 9: R = 0C(O)Ph 7: R = OC(0)Ph
H-Val-Pro-OMe*HCI 2
Boc-Val-OH (3.00g, 13.8mmol) was dissolved in 10ml of dry THF and cooled down to -15°C. To the mixture CAIBE (1.80ml, 13.8mmol) and NMM (1.52ml, 13.8mmol) where added and the solution was stirred until the formation of the mixed anhydride was complete. Then the mixture was brought to -10°C and NMM (1.52ml, 13.8mmol) was added followed by H-Pro-OMe*HCI (2.29g, 13.8mmol). The mixture was allowed to reach room temperature and left overnight. After removing the solvent and the usual workup the resulting ester 1 was taken without further characterisation. The ester 1 was dissolved in HCI/HOAc (5ml, 6N) and left at 0°C until the removal of the Boc-group was complete. The solvent was then removed and the resulting oil was treated with diethylether to give a white solid 2. Yield: 2.5g, 80% Z-Ala-Val-Pro-OMe 3
Z-Ala OH (3.5g, 15.7mmol) and 2 (4.18g, 15.7mmol) where treated in the same manner as above for 7, to give 3 as a white solid.
Yield: 4.2g, 64% Z-AIa-Val-Pro-OH 4
3 (4.2g, 9.6mmol) was dissolved in 30 ml of water/acetone (1/5 v/v) and 11.6ml NaOH (1 N) where added. After completion of the reaction the organic solvent was removed by evaporation and the resulting solution was diluted by 15ml NaHCO3 solution (saturated). Then the mixture was extracted three times by 10ml of acetic acid ethyl ester. After that the solution was brought to pH2 by adding HCI (15% in water). The resulting mixture was extracted three times by 30ml of acetic acid ethyl ester. The organic layer was separated and washed three times with brine, dried (Na2SO ) and evaporated.
Yield: 3.5g ,87% Z-Ala-Val-Pro-CH2-Br 5
4 (2.00g, 4.76mmol) was dissolved in 15ml of dry THF and converted into a mixed anhydride (see compound 1) using CAIBE (0.623ml, 4.76mmol) and NMM (0.525 ml, 4.76mmol). The precipitate formed was filtered off and cooled down to -15°C. Then diazomethane (23.8mmol in 30ml ether) was dropped into the solution under an argon atmosphere. After leaving the mixture for 1h at 0°C 1.27ml of HBr (33% in AcOH) was added and the solution was stirred for 30min at room temperature. After that 70 ml of ether was added and the mixture was washed with 20 ml of water. The organic layer was separated and dried (Na2SO ) and evaporated. Yield (crude): 1.8g , 80%
Z-protected acyloxymethylene ketones
The acid (2eq) was dissolved in DMF and an equimolar amount of KF was added. The suspension was allowed to stir at room temperature for 1 hour. Then the brommethylene (1eq) component was added and the solution was allowed to stir overnight. After that the solvent was removed under vacuum and the resulting oil was dissolved in chloroform and washed with brine. Then the organic layer was separated dried (Na2SO ) and the solvent was removed. The product was purified by column chromatography using silica gel and heptane/chloroform.
Z-Ala-Val-Pro-CH2O-C(O)-CH3 6
Acetic acid (230μl, 4.02mmol), KF (0.234g, 4.02mmol), 5 (1.00g, 2.01 mmol) Yield: 0.351 g, 36% Z-Ala-Val-Pro-CH2O-C(O)-Ph 7
Benzoic acid (0.275g, 2.25mmol), KF (0.131 mg, 2.25mmol), 5 (0.56g. 1.13mmol)
Yield: 0.34g, 56%
Deprotection
The Z-protected compound was dissolved in HBr/AcOH and stirred. When the reaction was complete ether was added, the white precipitate formed was filtered off and dried. H-Ala-Val-Pro-CH2O-C(O)CH3*HBr 8
6 (0.351g, 0,73mmol) Yield: 0.252g, 98% H-Ala-Val-Pro-CH2O-C(O)Ph*HBr 9
7 (0.34g, 0.63mmol) Yield: 0,251 g, 99% Example 5: Synthesis Of Cycloalkylketones
Figure imgf000048_0001
Boc-isoleucinal 2
Oxalylchloride (714 μl, 8.28 mmol) was dissolved in 10 ml of dry dichlormethane and brought to -78°C. Then DMSO (817 μl, 8.28 mmol) was added dropwise. The solution was stirred for 20 min at -78°C. Then 1 (1.00 g, 4.6 mmol) was added and the mixture was stirred for 20 min. After that TEA (2.58 ml, 18.4 mmol) was added and the mixture was allowed to reach room temperature. The mixture was diluted with hexane/ethylacetate (2/1 v/v) and 10 ml of HCI (10% in water) was added. The organic layer was separated and the aqueous phase was extracted with 20 ml of methylenechloride. All organic layers were collected and washed with brine, followed by water, then dried. The product was purified by column chromatography using silica gel and heptane/chloroform. Yield: 0.52 g, 52% terf-butyl Λ/-1 -[cyclopentyl(hydroxy)methyl]-2-methylbutylcarbamate 3
2 (0.52 g, 2.42 mmol) was dissolved in 10 ml of dry THF and cooled down to 0°C. Then cyclopentylmagnesiumbromide (1.45 ml of a 2 M solution) was added. After completion of the reaction (2 ml) of water was added and solution was neutralized by adding aqueous HCI. Then methylenechloride was added and the organic layer was separated and dried (Na2SO ). After evaporation the resulting oil was used without further characterisation. terf-butyl Λ/-[1-(cyclopentylcarbonyl)-2-methylbutyl]carbamate 4
3 (0.61 g, 2.15 mmol) was treated like 1. Oxalylchloride (333 μl, 3.87 mmol), DMSO (382 μl, 5.37 mmol), TEA (1.2 ml, 8.59 mmol)
Yield: 0.180 g, 30% 1-cyclopentyI-3-methyl-1-oxo-2-pentanaminium chloride 5
4 (0.18 g, 0.63 mmol) was dissolved in 2 ml HCI (7 N in dioxane). After completion of the reaction the solvent was removed and the resulting oil was purified by column chromatography on silical gel using a chloroform/methanol/water gradient. The resulting oil was triturated with ether.
Yield: 0.060 g, 54%
Example 6: Synthesis Of Side Chain Modified DPIV-lnhibitors
6.1 Synthesis of Boc-Glu-Thia
Reaction of Boc-Glu(OMe)-OH with Thia*HCI according to Method B (see section 6.4 for methods), hydrolysis of Boc-Glu(OMe)-Thia according to Method G
6.7.7 Analytical data for Boc-glutmyl thiazolidine
Figure imgf000049_0001
System A: chloroform/methanol 90:10
System B: benzene/acetone/acetic acid 25:10:0.5
System C: n-butanol/EA/acetic acid/H2O 1 :1 :1 :1
2 HPLC separation conditions Column: Nucleosil C-18, 7μ, 250 mm x 21 mm ' Eluant: isocratic, 40 % ACN/water/0.1 % TFA Flow rate: 6 ml/min λ = 220 nm
6.2 Side chain-modified Boc-glutamyl thiazolidines
Boc-Glu-Thia was modified at the γ-carboxylic acid function by introducing radicals of varying size. The radicals were coupled by way of their amino group by forming an amide bond to the γ-carboxylic acid function, with a variety of coupling methods being used depending on the radical. The following amino components were attached to Boc-Glu-Thia using the method stated:
Figure imgf000050_0001
In 2 cases, purification of the reaction products differs from the general description of synthesis. Boc-Glu(Gly5)-Thia
The product already precipitates out from the mixture on stirring overnight; it is subsequently filtered off and washed with 0.1 N HCI and copious amounts of water and then dried over P Oι0 In vacuo. Boc-Glu(PEG)-Thia In contrast to the general procedure, the starting materials for the synthesis are dissolved in a 500-fold excess of DMF. After the reaction is complete, the DMF is completely removed in vacuo and the residue is dissolved in a large amount of methanol. After ether is poured on, to form an upper layer, the product precipitates out together with the unreacted PEG. Fine purification was carried out by preparative HPLC separation on a gel filtration column (Pharmazia, Sephadex G-25, 90 μm, 260 mm - 100 mm). Separating conditions: eluant: water; flow rate: 5 ml/min; λ = 220 nm
Figure imgf000051_0001
Column: Nucleosil C-18, 7μ, 250 mm x 21 mm Eluant: isocratic, 40 % ACN/water/0.1 % TFA Flow rate: 6 ml/min λ = 220 nm
6.3 Side chain-modified glutamyl thiazolidines
The N-terminal Boc protecting groups were cleaved off the compounds described in Table 6.2.2 using method F. The substances modified with Gly derivatives were purified by preparative HPLC separation and are present as trifluoroacetates. The H-Glu(PEG)-Thia was purified on a gel filtration column in the same manner as the Boc-protected precursor.
6.3.1 Synthesis data for side chain-modified glutamyl thiazolidines
Figure imgf000052_0001
HPLC separation conditions Column: Nucleosil C-18, 7μ, 250 mm x 21 mm Eluant: ACN/water/0.1 % TFA Gradient: 20 % ACN - 90 % ACN over 30 min Flow rate: 6 ml/min λ = 220 nm n.dm. - not determined or not determinable
6.4 General synthesis procedures
Method A: Peptide bond attachment by the mixed anhydride method using CFIBE as activation reagent 10 mmol of N-terminally protected amino acid or peptide are dissolved in 20 ml of absolute THF. The solution is cooled to -15°C + 2°C. With stirring in each case, 10 mmol of N-MM and 10 mmol of chloroformic acid isobutyl ester are added in succession, the stated temperature range being strictly adhered to. After approximately 6 min, 10 mmol of the amino component is added. When the amino component is a salt, a further 10 mmol of N-MM is then added to the reaction mixture. The reaction mixture is then stirred for 2 h in the cold state and overnight at room temperature.
The reaction mixture is concentrated using a rotary evaporator, taken up in EA, washed with 5 % KH2SO4 solution, saturated NaHCO3 solution and saturated NaCl solution and dried over NaSO4. After removal of the solvent in vacuo, the compound is recrystallized from EA/pentane.
Method B: Peptide bond attachment by the mixed anhydride method using pivalic acid chloride as activation reagent
10 mmol of N-terminally protected amino acid or peptide are dissolved in 20 ml of absolute THF. The solution is cooled to 0°C. With stirring in each case, 10 mmol of N-MM and 10 mmol of pivalic acid chloride are added in succession, the stated temperature range being strictly adhered to. After approximately 6 min, the mixture is cooled to -15°C and, once the lower temperature has been reached, 10 mmol of the amino component is added. When the amino component is a salt, a further 10 mmol of N-MM is then added to the reaction mixture. The reaction mixture is then stirred for 2 h in the cold state and overnight at room temperature.
Further working up is carried out as in Method A.
Method C: Peptide bond attachment using TBTU as activation reagent
10 mmol of the N-terminally protected amino acid or peptide and 10 mmol of the C-terminally protected amino component are dissolved in 20 ml of absolute DMF. The solution is cooled to 0°C. With stirring in each case, 10 mmol of DIPEA and 10 mmol of TBTU are added in succession. The reaction mixture is stirred for one hour at 0°C and then overnight at room temperature. The DMF is completely removed in vacuo and the product is worked up as described in Method A.
Method D: Synthesis of an active ester (N-hydroxysuccinimide ester)
10 mmol of N-terminally protected amino acid or peptide and 10 mmol of N- hydroxysuccinimide are dissolved in 20 ml of absolute THF. The solution is cooled to 0°C and 10 mmol of dicyclohexylcarbodiimide are added, with stirring. The reaction mixture is stirred for a further 2 h at 0°C and then overnight at room temperature. The resulting N.N'-dicyclohexylurea is filtered off and the solvent is removed in vacuo and the remaining product is recrystallized from EA/pentane.
Method E: Amide bond attachment using N-hydroxysuccinimide esters
10 mmol of the C-terminally unprotected amino component is introduced into an NaHCO3 solution (20 mmol in 20 ml of water). At room temperature and with stirring, 10 mmol of the N-terminally protected N-hydroxysuccinimide ester dissolved in 10 ml of dioxane are slowly added dropwise. Stirring of the reaction mixture is continued overnight and the solvent is then removed in vacuo.
Further working up is carried out as in Method A.
Method F: Cleavage of the Boc protecting group
3 ml of 1.1 N HCI/glacial acetic acid (Method F1) or 3 ml of 1.1 N HCI/dioxane (Method F2) or 3 ml of 50 % TFA in DCM (Method F3) are added to 1 mmol of Boc- protected amino acid pyrrolidide, thiazolidide or peptide. The cleavage at RT is monitored by means of TLC. After the reaction is complete (approximately 2 h), the compound is precipitated in the form of the hydrochloride using absolute diethyl ether and is isolated with suction and dried over P4O10 in vacuo. Using methanol/ether, the product is recrystallized or reprecipitated. Method G: Hydrolysis
1 mmol of peptide methyl ester is dissolved in 10 ml of acetone and 11 ml of 0.1 M NaOH solution and stirred at room temperature. The course of the hydrolysis is monitored by means of TLC. After the reaction is complete, the acetone is removed in vacuo. The remaining aqueous solution is acidified, using concentrated KH2SO4 solution, until a pH of 2-3 is reached. The product is then extracted several times using EA; the combined ethyl acetate fractions are washed with saturated NaCl solution and dried over NaSO4, and the solvent is removed in vacuo. Crystallization from EA/pentane is carried out.
Example 7: Kj-determination
For Ki determination of glutaminyl pyrrolidine and glutaminyl thiazolidine, dipeptidyl peptidase IV from porcine kidney with a specific activity against glycylprolyl- 4-nitroaniline of 37.5 U/mg and an enzyme concentration of 1.41 mg/ml in the stock solution was used.
Assay mixture:
100 μl test compound in a concentration range of 1*10"5 M - 1*10"8 M were admixed with 50 μl glycylprolyl-4-nitroaniline in different concentrations (0.4 mM, 0.2 mM, 0.1 mM, 0,05 mM) and 100 μl HEPES (40 mM, pH7.6; ion strength = 0.125). The assay mixture was pre-incubated at 30 °C for 30 min. After pre-incubation, 20 μl DPIV (1 :600 diluted) was added and measurement of yellow color development due to 4-nitroaniline release was performed at 30°C and = 405 nm for 10 min. using a plate reader (HTS7000 plus, Applied Biosystems, Weiterstadt, Germany).
The Ki-values were calculated using Graphit version 4.0.13, 4.0.13 and 4.0.15 (Erithacus Software, Ltd, UK). 7.7 Results - K values of DPIV inhibition
Figure imgf000056_0001
Figure imgf000057_0001
^-butyl-Gly is defined as:
Figure imgf000058_0001
Ser (P) and Ser (Bzl) are defined as phosphorylserine and benzylserine. Tyr (P) is defined as phosporyltyrosine.
Example 8: Determination of IC5o-Values
100 μl inhibitor stock solution were mixed with 100 μl buffer (HEPES pH7.6) and 50 μl substrate (Gly-Pro-pNA, final concentration 0.4 mM) and preincubated at 30°C. Reaction was started by addition of 20 μl purified porcine DPIV. Formation of the product pNA was measured at 405 nm over 10 min using the HTS 7000Plus plate reader (Perkin Elmer) and slopes were calculated. The final inhibitor concentrations ranged between 1 mM and 30 nM. For calculation of IC50 GraFit 4.0.13 (Erithacus Software) was used.
8.1 Results - Determination of IC50 values
Figure imgf000058_0002
Figure imgf000059_0001
Ser (P) and Ser (Bzl) are defined as phosphorylserine and benzylserine. Tyr (P) is defined as phosporyltyrosine.
Example 9: Inhibition Of DPIV-Like Enzymes - Dipeptidyl Peptidase II
DP 11 (3.4.14.2) releases N-terminal dipeptides from oligopeptides if the N- terminus is not protonated (McDonald, J.K., Ellis, S. & Reilly, T.J., 1966, J. Biol. Chem., 241 , 1494-1501 ). Pro and Ala in Pi-position are preferred residues. The enzyme activity is described as DPIV-like activity, but DP II has an acidic pH-optimum. The enzyme used was purified from porcine kidney.
Assay:
100 μl glutaminyl pyrrolidine or glutaminyl thiazolidine in an concentration range of 1*10"4 M - 5*10"8 M were admixed with 100 μl μl buffer solution (40 mM HEPES, pH7.6, 0.015% Brij, 1 mM DTT), 50 μl lysylalanylaminomethylcoumarine solution (5 mM) and 20 μl porcine DP II (250fold diluted in buffer solution). Fluorescence measurement was performed at 30°C and λeXcitation = 380 nm, λΘmission = 465 nm for 25 min using a plate reader (HTS7000plus, Applied Biosystems, Weiterstadt, Germany). The Ki-values were calculated using Graphit 4.0.15 (Erithacus Software, Ltd., UK) and were determined as Ki = 8.52*10'5 M ± 6.33*10"6 M for glutaminyl pyrrolidine and Ki = 1.07*10"° M ± 3.81 *10"7 M for glutaminyl thiazolidine.
Example 10: Cross Reacting Enzymes
Glutaminyl pyrrolidine or glutaminyl thiazolidine were tested for their cross reacting potency against dipeptidyl peptidase I, prolyl oligopeptidase and Prolidase.
Dipeptidyl peptidase I (DP I, cathepsin C): DP I or cathepsin C is a lysosomal cysteine protease which cleaves off dipeptides from the N-terminus of their substrates (Gutman, H.R. & Fruton, J.S., 1948, J. Biol: Chem., 174, 851-858) . It is classified as a cysteine protease. The enzyme used was purchased from Qiagen (Qiagen GmbH, Hilden, Germany). In order to get a fully active enzyme, the enzyme was diluted lOOOfold in MES buffer pH5,6 (40 mM MES, 4 mM DTT, 4 mM KCI, 2 mM EDTA, 0.015% Brij) and pre-incubated for 30 min at 30°C.
Assay:
50 μl glutaminyl pyrrolidine or glutaminyl thiazolidine in a concentration range of 1*10"5 M - 1*10"7 M were admixed with 110 μl buffer-enzyme-mixture. The assay mixture was pre-incubated at 30 °C for 15 min. After pre-incubation, 100 μl histidylseryl-βnitroaniline (2*10"5M) was added and measurement of yellow color development due to β-nitroaniline release was performed at 30°C and λexCitation = 380 nm, λemission = 465 nm for 10 min., using a plate reader (HTS7000 plus, Applied Biosystems, Weiterstadt, Germany).
The IC 50-values were calculated using Graphit 4.0.15 (Erithacus Software, Ltd., UK). No inhibition of the DP l enzyme activity by glutaminyl pyrrolidine or glutaminyl thiazolidine was found.
Prolyl oligopeptidase (POP)
Prolyl oligopeptidase (EC 3.4.21.26) is a serine type endoprotease which cleaves off peptides at the N-terminal part of the Xaa-Pro bond (Walter, R., Shlank, H., Glass, J.D., Schwartz.l.L. & Kerenyi, T.D., 1971 , Science, 173, 827-829). Substrates are peptides with a molecular weight up to 3000 Da. The enzyme used was a recombinant human prolyl oligopeptidase. Recombinant expression was performed in E. coli under standard conditions as described elsewhere in the state of the art. Assay:
100 μl glutaminyl pyrrolidine or glutaminyl thiazolidine in an concentration range of 1*10"4 M - 5*10"8 M were admixed with 100 μl μl buffer solution (40 mM HEPES, pH7.6, 0.015% Brij, 1 mM DTT) and 20 μl POP solution. The assay mixture was preincubated at 30 °C for 15 min. After pre-incubation, 50 μl giycylprolylprolyl-4- nitroaniline solution (0.29 mM) was added and measurement of yellow color development due to 4-nitroaniline release was performed at 30°C and λ = 405 nm for 10 min using a plate reader (sunrise, Tecan, Crailsheim, Germany). The IC 5o-values were calculated using Graphit 4.0.15 (Erithacus Software, Ltd., UK). No inhibition of POP activity by glutaminyl pyrrolidine or glutaminyl thiazolidine was found.
Prolidase (X-Pro dipeptidase)
Prolidase (EC 3.4.13.9) was first described by Bergmann & Fruton (Bergmann, M. & Fruton, JS, 1937, J. Biol. Chem. 189-202). Prolidase releases the N-terminal amino acid from Xaa-Pro dipeptides and has a pH optimum between 6 and 9.
Prolidase from porcine kidney (ICN Biomedicals, Eschwege, Germany), was solved (1 mg/ml) in assay buffer (20mM NH4(CH3COO)2, 3mM MnCI2, pH 7.6). In order to get a fully active enzyme the solution was incubated for 60 min at room temperature.
Assay:
450 μl glutaminyl pyrrolidine or glutaminyl thiazolidine in an concentration range of 5*10'3 M - 5*10'7 M were admixed with 500 μl buffer solution (20mM NH4(CH3COO)2, pH 7.6) and 250 μl lle-Pro-OH (0.5mM in the assay mixture). The assay mixture was pre-incubated at 30 °C for 5 min. After pre-incubation, 75 μl Prolidase (1 :10 diluted in assay buffer) were added and measurement was performed at 30°C and λ = 220 nm for 20 min using a UV/Vis photometer, UV1 (Thermo Spectronic, Cambridge, UK).
The IC 5o-values' were calculated using Graphit 4.0.15 (Erithacus Software, Ltd., UK). They were determined as IC 50 > 3mM for glutaminyl thiazolidine and as IC 50 = 3.4*10" M ± 5.63*10"5 for glutaminyl pyrrolidine.
Example 11 : Determination Of DPIV Inhibiting Activity After Intravasal And Oral Administration To Wistar Rats
Animals
Male Wistar rats (Shoe: Wist(Sho)) with a body weight ranging between 250 and 350 g were purchased from Tierzucht Schδnwalde (Schδnwalde, Germany).
Housing conditions
Animals were single-caged under conventional conditions with controlled temperature (22±2 °C) on a 12/12 hours light/dark cycle (light on at 06:00 AM). Standard pelleted chow (ssniff® Soest, Germany) and tap water acidified with HCI were allowed ad libitum.
Catheter insertion into carotid artery
After ≥one week of adaptation at the housing conditions, catheters were implanted into the carotid artery of Wistar rats under general anaesthesia (i.p. injection of 0.25 ml/kg b.w. Rompun® [2 %], BayerVital, Germany and 0.5 ml/kg b.w. Ketamin 10, Atarost GmbH & Co., Twistringen, Germany). The animals were allowed to recover for one week. The catheters were flushed with heparin-saline (100 lU/ml) three times per week. In case of catheter dysfunction, a second catheter was inserted into the contra-lateral carotid artery of the respective rat. After one week of recovery from surgery, this animal was reintegrated into the study. In case of dysfunction of the second catheter, the animal was withdrawn from the study. A new animal was recruited and the experiments were continued in the planned sequence, beginning at least 7 days after catheter implantation.
Experimental design
Rats with intact catheter function were administered placebo (1 ml saline, 0.154 mol/l) or test compound via the oral and the intra-vasal (intra-arterial) route. After overnight fasting, 100 μl samples of heparinised arterial blood were collected at -30, -5, and 0 min. The test substance was dissolved freshly in 1.0 ml saline (0.154 mol/l) and was administered at 0 min either orally via a feeding tube (75 mm; Fine Science Tools, Heidelberg, Germany) or via the intra-vasal route. In the case of oral administration, an additional volume of 1 ml saline was injected into the arterial catheter. In the case of intra-arterial administration, the catheter was immediately flushed with 30 μl saline and an additional 1 ml of saline was given orally via the feeding tube.
After application of placebo or the test substances, arterial blood samples were taken at 2.5, 5, 7.5, 10, 15, 20, 40, 60 and 120 min from the carotid catheter of the conscious unrestrained rats. All blood samples were collected into ice cooled Eppendorf tubes (Eppendorf-Netheler-Hinz, Hamburg, Germany) filled with 10 μl 1 M sodium citrate buffer (pH 3.0) for plasma DPIV activity measurement. Eppendorf tubes were centrifuged immediately (12000 rpm for 2 min, Hettich Zentrifuge EBA 12, Tuttlingen; Germany): The plasma fractions were stored on ice until analysis or were frozen at -20 °C until analysis. All plasma samples were labelled with the following data:
• Code number
• Animal Number • Date of sampling
• Time of sampling
Analytical Methods
The assay mixture for determination of plasma DPIV activity consisted of 80 μl reagent and 20 μl plasma sample. Kinetic measurement of the formation of the yellow product 4-nitroaniline from the substrate glycylprolyl-4-nitroaniline was performed at 390 nm for 1 min at 30 °C after 2 min pre-incubation at the same temperature. The DPIV activity was expressed in mU/ml.
Statistical methods
Statistical evaluations and graphics were performed with PRISM® 3.02 (GraphPad Software, Inc.). All parameters were analysed in a descriptive manner including mean and SD.
7.7 Results - in vivo DPIV-inhibition at t, max
Figure imgf000065_0001
Figure imgf000066_0001
Example 12: Action Of Side Chain-Modified Glutamylthiazolidines As Non- Readily-Transportable DPIV-lnhibitors
Side chain-modified glutamylthiazolidines having a structure H-Glu(X)-Thia were synthesised, with polyethylene glycol or glycine oligomers of various chain lengths being used as X (see Method A of example for description of synthesis). The binding characteristics of those derivatives and their transportability by the peptide transporter PepT1 were investigated.
Surprisingly, it was found that the side chain modifications alter the binding characteristics of the compounds to DPIV only to a slight extent. In contrast, the ability of the inhibitors to be transported by the peptide transporter is dramatically diminished by the side chain modification.
Side chain modified inhibitors of DPIV or DPIV-like enzymes are therefore well suited to achieving site directed inhibition of DPIV in the body.
72.7 Results: Transportability of selected DPIV-inhibitors.
Figure imgf000066_0002
Figure imgf000067_0001
1 Effective concentrations of the compounds inhibiting the binding of 3H-D-Phe-Ala (80mM) to PepT1 -expressing P. pastoris cells by 50 % (EC50 values)
2 Transport characteristics at PepT1 -expressing oocytes of X. leavis - by means of two-electrode voltage clamp method, I = inward currents generated by the transport
Example 13: Efficacy Of Dipeptidyl-Peptidase IV (DPIV; CD26) Inhibitors In Models For Multiple Sclerosis
73.7 Experiment 1: i.p. treatment (0-30 mg/kg b.w. isoleucyl thiazolidine fumarate/day) from day 1-15. Scores until day 15 p.i.
Materials and methods
Animals
For the first experiment female inbred Lewis rats (t? = 50) with a mean body weight of 190 ± 6g, were obtained from Charles River (Bad Sulzfeld, Germany). Animals were randomly assigned to the different experimental conditions. Rats were housed four per cage under a 12:12 h light: dark cycle (lights off at 18:00 h) and at constant temperature (24°C) in a specific pathogen free air-conditioned colony room with food (Altromin lab chow pellets) and tap water available ad lib. The animals underwent routine cage maintenance once a week. Induction of EAE
Guinea pig MBP (50 μg/rat) was emulsified in Complete Freund's adjuvant (CFA) containing heat-killed Mycobacterium tuberculosis (H37Ra; 225 μg/rat) and injected s.c. at the base of the tail in a total volume of 100 μl (12). CFA (Sigma) and heat-killed Mycobacterium tuberculosis (H37Ra) were purchased from Life Technologies, Inc. (Rockville, MD). Clinical disease was scored on the following scale: 0.5: partial loss of tail tone; 1.0: complete tail atony; 2.0: hind limb weakness; 2.5: hind limb paralysis of one leg; 3.0: hind limb paralysis of both legs; 3.5: limb paralysis of three legs; 4.0: quadriplegia and moribund status; 5.0: death due to EAE. Experiments were terminated on day 15 post immunization when most of the animals were about 48h after maximal clinical score. The incidence of adjuvant-induced arthritis was remarkably low (π=0 in the 1st experiment) using the base of the tail as an immunization site. In general, animals exhibiting signs of arthritis or not developing any signs of EAE or showing signs of peritonitis on autopsy were excluded from further analysis. In the first experiment no signs of arthritis and no sudden deaths and/or peritonitis due to repeated ip-injection were found. Two animals in the 1mg/kg- treatment-group did not develop clear signs of EAE (score > 1 ) and therefore were excluded from further analysis although this eventually might reflect a treatment effect. Immunization at the base of tail might cause acute inflammation, which in turn might affect the tone of the tail during the first days post immunization.
Statistical analysis
Comparison over time between the clinical course of EAE of the different treatment conditions was conducted using a two factorial analysis of variance (ANOVA) for repeated measures. Sums of clinical scores of EAE, onset and peak of disease were calculated on the basis of the clinical scores per day and analyzed using a one factorial ANOVA and post hoc Fisher's PLSD tests, if appropriate. All data are presented as means ± SEM. Results
Effect of daily injections of isoleucyl thiazolidine fumarate on clinical course of EAE in Lewis rats
The clinical course of the EAE is illustrated in Figure 1. Two factor ANOVA for repeated measures (treatment x clinical scores over time) revealed a significant interaction of the two factors (F(4,56) = 1.7; p = 0.001 ) indicating a differential course of the disease. This interaction is most probably due to the fact that inhibitor treatment aggravated the initial course of EAE while it improved recovery from disease.
Separate one factor ANOVAs split by day revealed significant (day 11 : F(4,43) = 2.8; p < 0.05; day 12: F(4,43) = 3.0; p < 0.05) disease-aggravating effects at the 1mg dosage on days 11 and 12 post immunization (p.i.), while the 10mg dose significantly (F(4,43) = 4.8; p < 0.001 ) reduced clinical score at day 15 p.i. This again indicates that the inhibitor initially tends to aggravate the disease while at later stages it results in an accelerated recovery from disease. Further analysis of key parameter derived from the clinical course demonstrated that inhibitor treatment at the 10mg/kg dosage shortened the latency until onset of disease for about 1 day.
Conclusion
Daily intraperitoneal treatment with the DPIV-inhibitor isoleucyl thiazolidine fumarate over a wide range of dosages in Lewis rats for a period of 15 days post immunization with MBP in CFA showed that the drug initially aggravates and during recovery phase improves the clinical course of the disease. It is possible that initial pro-inflammatory effects during acute disease may switch into anti-inflammatory or other clinics improving effects after reaching peak of disease. These late effects may overall be beneficial. Further experiments will test this hypothesis by comparing "early" vs. "late" or "induction" vs. "ongoing" disease effects. 73.2 Experiment 2: i.p. treatment (0-30 mg/kg b.w. isoleucyl thiazolidine fumarate/day) from day 5-15. Scores until day 21 p.i.
Materials and methods
Animals
For the second experiment, male inbred Lewis rats (n = 50) with a mean body weight of 230 ± 12g, were obtained from Charles River (Bad Suizfeld, Germany). Animals were randomly assigned to the different experimental conditions. Rats were housed four per cage under a 12:12 h light: dark cycle (lights off at 18:00 h) and at constant temperature (24°C) in a specific pathogen free air-conditioned colony room with food (Altromin lab chow pellets) and tap water available ad lib. The animals underwent routine cage maintenance once a week.
Induction of EAE
Guinea pig MBP (50 μg/rat) was emulsified in Complete Freund's adjuvant (CFA) containing heat-killed Mycobacterium tuberculosis (H37Ra; 225 μg/rat) and injected s.c. at the base of the tail in a total volume of 100 μl (12). CFA (Sigma) and heat-killed Mycobacterium tuberculosis (H37Ra) were purchased from Life Technologies, Inc. (Rockville, MD). Clinical disease was scored on the following scale: 0.5: partial loss of tail tone; 1.0: complete tail atony; 2.0: hind limb weakness; 2.5: hind limb paralysis of one leg; 3.0: hind limb paralysis of both legs; 3.5: limb paralysis of three legs; 4.0: quadriplegia and moribund status; 5.0: death due to EAE. Experiments were terminated on day 21 post immunization (p.i.).
General observations during EAE in the second experiment The incidence of adjuvant-induced arthritis was remarkably low (t?=0 in the 2nd experiment) using the base of the tail as an immunization site. In the second experiment no signs of arthritis were found. Surprisingly, and similar in comparison with the first experiment, four animals in the 1 mg/kg-treatment-group did not develop clear signs of EAE (score > 1 ). This time, these animals remained in the analysis, because this finding is probably due to the treatment. In this experiment a phenomenon called "disease dissociation" was observed. In several animals there was a clear tonus of the tail associated with a clear weakness of the hind limbs. The animals were scored maximal, i.e. 2.
Statistical analysis
Comparison over time between the clinical course of EAE of the different treatment conditions was conducted using a two factorial analysis of variance (ANOVA) for repeated measures. Sums of clinical scores of EAE, onset and peak of disease were calculated on the basis of the clinical scores per day and analyzed using a one factorial ANOVA and post hoc Fisher's PLSD tests, if appropriate. All data are presented as means ± SEM.
Results
Effect of daily injections of isoleucyl thiazolidine fumarate during ongoing EAE in male
Lewis rats
The clinical course of the EAE is illustrated in Figure 3. Two factor ANOVA for repeated measures (treatment x clinical scores over time) revealed a significant effect for the factor treatment (F(4,45) = 4.3; p = 0.0048) and a significant interaction of the two factors (F(4,45) = 3.5; p < 0.0001 ) indicating a differential course of the disease. This interaction is most probably due to the fact that low dose inhibitor treatment aggravated or even "induced" an early peak in the initial course of EAE while high dose improved deary inhibited the acute phase of the disease. Separate one factor ANOVAs split by day revealed significant disease aggravating effects in two peaks of the disease. The 3mg and 10mg dosages induced a significant first peak of disease activity directly after initiation of treatment on days 6-9 (see figure 3; day 6: F(4,41 ) = 6.7; p = 0.0003; day 7: F(4,41) = 13.4; p < 0.0001 ; day 8: F(4,41) = 10.0; p < 0.0001; day 9: F(4,41 ) = 6.0; p = 0.0007). In the second peak, the "classical acute EAE", which was more severe than the first one, the 1mg dose aggravate the clinical scores while the high dosage of 30mg/kg exerted significant delaying and ameliorating effects (see figure 4; day 10: F(4,41 ) = 16; p < 0.0001 ; day 11 : F(4,41 ) = 13.5; p < 0.0001 ; day 12: F(4,41 ) = 8.0; p < 0.0001 ; day 13: F(4,43) = 3.4; p = 0.017). This indicates proinflammatory effects of low dose inhibitor treatment while high dose inhibitior acts protective or anti-inflammatory-like in this model of MS. Further analysis of key parameters derived from the clinical course demonstrated that inhibitor treatment at the 1 mg/kg dosage exerts pro-inflammatory effects while 30mg/kg mediated protective-like or anti-inflammatory effects with a delay in the onset.
Clinical scores of EAE in male Lewis rats treated from days 5-15(21 ) p.i.
isoleucyl thiazolidine fumarate
Scores Omg/k 1 mg/kg 3mg/kg 10mg/kg 30mg/kg
9
Onset of disease 1 1 "8 10'3* 2"° 2" 1 14"0***
(1st day of score >1)
Maximal score 2.6 2.8 3.0 2.1 2.0*
Sum of scores 10.2 14.2 12.0 10.8 5.6**
Average score 0.68 0.96 * 0.8 0.72 0.37**
The various key parameters derived from EAE scores significantly differ in rats treated with different dosages of isoleucyl thiazolidine fumarate from days 5-15. Proinflammatory effects of 1 mg and anti-inflammatory effects of 30mg/kg are evident. Data represent means. *p<0.05, **p<0.01 , ***p<0.0001 vs. control. Conclusion
This experiment investigated the effects of daily intraperitoneal treatment with the DPIV-inhibitor isoleucyl thiazolidine fumarate over a wide range of dosages in male Lewis rats for 10 days with the treatment being initiated at day 5 post immunization with MBP in CFA. Treatment caused a significant dose-dependent and bimodal treatment effect in this design and model for MS. Low dose (1 mg) of the drug initially aggravates the acute phase of EAE. Moderate dose of isoleucyl thiazolidine fumarate (3 and 10mg) induces an early "first peak" of disease directly after initiation of disease, suggestive for direct pro-inflammatory effects in vivo. High dose of the drug (30mg) exerts clearly a potent anti-inflammatory effect and a delay in the onset of disease.
13.3 Experiment 3: i.v. treatment during ongoing disease; 0-50 nmol isoleucyl thiazolidine fumarate/5 μl per rat daily from days 5-15)
Materials and method
Animals
For the 3rd experiment female inbred Lewis rats (n - 50) with a mean body weight of 201 ± 5g, were obtained from Charles River, Germany. Animals were randomly assigned to the different experimental conditions. Rats were housed four per cage under a 12:12 h light: dark cycle (lights off at 18:00 h) and at constant temperature (24°C) in a specific pathogen free air-conditioned colony room with food (Altromin lab chow pellets) and tap water available ad lib. The animals underwent routine cage maintenance once a week.
Surgery and ev. application Under ketamine/xylasine (100/5 mg/kg, i.p.) anesthesia, the rats were fixed in a Kopf stereotaxic frame and implanted with cannulae (Plastic One, Inc., Roanoke, VA, USA) above the lateral ventricle, (coordinates: A:-0.7mm caudal, L:1.4mm lateral to bregma; and V:3.2mm ventral to the skull surface; tooth bar +3.0 above ear bars) using standard stereotaxic procedures as described in detail elsewhere. After a 4-day recovery period, rats were habituated to experimental handling by daily sham injections for another three days. On day seven after i.e. v. cannula implantation, EAE was induced
Induction of EAE
Guinea pig MBP (50 μg/rat) was emulsified in Complete Freund's adjuvant (CFA) containing heat-killed Mycobacterium tuberculosis (H37Ra; 225 μg/rat) and injected s.c. at the base of the tail in a total volume of 100 μl (12). CFA (Sigma) and heat-killed Mycobacterium tuberculosis (H37Ra) were purchased from Life Technologies, Inc. (Rockville, MD). Clinical disease was scored on the following scale: 0.5: partial loss of tail tone; 1.0: complete tail atony; 1.5: complete tail atony and weakness of one hind limb; 2.0: weakness of both hind limbs; 2.5: hind limb weakness and paralysis of one hind leg; 3.0: paralysis of both hind legs; 3,5: limb paralysis of three legs; 4.0: quadriplegia and moribund status; 5.0: death due to EAE. Experiments were terminated on day 15 post immunization (p.i.).
General observations during EAE in the 3rd experiment
In the 3rd experiment no signs of arthritis were found. One animal of the vehicle control group lost the icv-cannula and was excluded from further analysis. All other animals tolerated the treatment without any signs of aversiveness or sickness.
Statistical analysis Comparison over time between the clinical courses of EAE of the different treatment conditions was conducted using a two factorial analysis of variance (ANOVA) for repeated measures. Sums of clinical scores of EAE, onset and peak of disease were calculated on the basis of the clinical scores per day and analyzed using a one factorial ANOVA and post hoc Fisher's PLSD tests, if appropriate. All data are presented as means + SEM.
Results
Effect of daily icv injections of isoleucyl thiazolidine fumarate during ongoing EAE in female Lewis rats
The clinical course of the EAE is illustrated in Figure 5. Two factor ANOVA for repeated measures (treatment x clinical scores over time) revealed a significant effect for the factor treatment (F(4,56) = 3.0; p = 0.03) and a significant interaction of the two factors (F(4,56) = 2.1 ; p < 0.0001 ) indicating a differential course of the disease. This interaction is most probably due to the fact that all dosages of the compound delayed and/or ameliorated the clinical course of EAE.
Further analysis of key parameter derived from the clinical course demonstrated that inhibitor treatment exerted anti-inflammatory effects on all parameters investigated
Clinical score of EAE in female Lewis rats treated icv from day 5-15 p.i.
isoleucyl thiazolidine fumarate
Scores 0 nmol 0.5 nmol 5 nmol 10 nmol 50 nmol
Onset of disease (1st 9.6 10.5 11.2* 12.5** 13.5*** day of score 1) Maximal score 2.5 2.75 2.0 2.0 1.6*
Sum of scores 11.5 10.6 6.5* 6.7* 4.9**
Average score 0.76 0.7 0.44* 0.45* 0.31**
The various key parameters derived from EAE scores significantly differ in rats treated with different dosages of isoleucyl thiazolidine fumarate from days 5-15. Dose-dependent and potent anti-inflammatory effects of 5-50 nmol are evident. Data represent means. *p<0.05, **p<0.01 , ***p<0.0001 vs. control.
Conclusion
This experiment investigated the effects of daily icv treatment with the DPIV- inhibitor isoleucyl thiazolidine fumarate over a wide range of dosages in female Lewis rats for 10 days with the treatment being conducted from day 5-15 post immunization with MBP in CFA. This design was aimed at investigating the effects of the drug on the cellular components constituting the local inflammation within the CNS during EAE. lev treatment with 5-50nmol dosages of isoleucyl thiazolidine fumarate caused a dose-dependent anti-inflammatory effect. These findings showpotent anti-inflammatory effect.

Claims

Claims
1. Use of at least one inhibitor of dipeptidyl peptidase IV (DPIV) or DPIV-like enzyme activity for reducing an immune, autoimmune or central nervous system related disorder selected from the group consisting of strokes, ischemia, Parkinson's disease, multiple sclerosis and migraines.
2. The use according to claim 1 , wherein the disorder is multiple sclerosis.
3. The use according to claims 1 or 2, wherein the dideptidyl peptidase IV-like enzyme is selected from the group consisting of fibroblast activation protein α, dipeptidyl peptidase IV β, dipeptidyl aminopeptidase-like protein, N-acetylated α- linked acidic dipeptidase, quiescent cell proline dipeptidase, dipeptidyl peptidase II, attractin, dipeptidyl peptidase IV related protein (DPP 8), dipeptidyl peptidase 9 (DPP 9), KIAA1492, DPRP1 , DPRP2 and DPRP3.
4. The use according to any one of the preceding claims, wherein the structure of the dideptidyl peptidase IV-like enzyme is undiscovered.
5. The use according to any one of the preceding claims, wherein the inhibitor is a dipeptide compound formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof.
6. The. use according to any one of the preceding claims, wherein the dipeptide compound is selected from the group consisting of L-fAVeo-isoleucyl pyrrolidine, L- a//o-isoleucyl thiazolidine, 1 -a//o-isoleucyl pyrrolydine, L-glutaminyl thiazolidine, L- glutaminyl pyrrolidine, L-glutamic acid thiazolidine, L-glutamic acid pyrrolidine and salts thereof. The use according to any one of claims 1 to 4, wherein the inhibitor is a peptide compound useful for competetive modulation of dipeptidyl peptidase IV catalysis represented by the general formula
K E
wherein
A is an amino acid except a D-amino acid;
B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)- carboxylic acid and pipecolic acid,
C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine,
D is any amino acid or missing, and
E is any amino acid or missing,
or:
C is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid, except N-alkylated amino acids, e.g. N-methyl valine and sarcosine and except a D-amino-acid;
D is any amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)- carboxylic acid and pipecolic acid, and
E is any amino acid except Pro, Hyp, acetidine-(2)-carboxylic acid, pipecolic acid and except N-alkylated amino acids, e.g. N-methyl valine and sarcosine.
The use according to any one of claims 1 to 4, wherein the inhibitor is a peptidylketone represented by the general formula
Figure imgf000079_0001
including all stereoisomers and pharmaceutically acceptable salts thereof, wherein
A is selected from :
Figure imgf000079_0002
X1 is H or an acyl or oxycarbonyl group or an amino acid or peptide residue,
X2 is H, -(CH)n-NH-C5H3N-Y with n=2-4 or C5H3N-Y (a divalent pyridyl residue) and Y is selected from H, Br, Cl, I, NO2 or CN, X3 is H or a phenyl or pyridyl residue, unsubstituted or substituted with one, two or more alkyl, alkoxy, halogen, nitro, cyano or carboxy residues, X4 is H or a phenyl or pyridyl residue, unsubstituted or substituted with one, two or more alkyl, alkoxy, halogen, nitro, cyano or carboxy residues, X5 is H or an alkyl, alkoxy or phenyl residue, X6 is H or an alkyl residue.
for n = 1
X is selected from: H, OR2, SR2, NR2R3, N+R2R3R4, wherein:
R2 stands for acyl residues, which are unsubstituted or substituted with one, two or more alkyl, cycloalkyl, aryl or heteroaryl residues, or for all amino acids and peptidic residues, or alkyl residues, which are unsubstituted or substituted with one, two or more alkyl, cycloalkyl, aryl and heteroaryl residues,
R3 stands for alkyl and acyl functions, wherein R2 and R3 may be part of one or more ring structures of saturated and unsaturated carbocyclic or heterocyclic structures,
R4 stands for alkyl residues, wherein R2 and R4 or R3 and R4 may be part of one or more ring structures of saturated and unsaturated carbocyclic or heterocyclic structures,
for n = 0 X is selected from:
Figure imgf000080_0001
wherein B stands for: O, S, NR5, wherein R5 is H, an alkyliden or acyl,
C, D, E, F, G, H are independently selected from unsubstituted and substituted alkyl, oxyalkyl, thioalkyl, aminoalkyl, carbonylalkyl, acyl, carbamoyl, aryl and heteroaryl . residues; and
for n= 0 and n=1
Z is selected from H, or a branched or single chain alkyl residue from C Cg or a branched or single chain alkenyl residue from C2-C9, a cycloalkyl residue from C3- C8, a cycloalkenyl residue from C -C7, an aryl- or heteroaryl residue, or a side chain selected from all side chains of all natural amino acids or derivatives thereof.
9. The use according to any one of claims 1 to 4 wherein the inhibitor is a aminoketone derivative represented by the general formulas 5, 6, 7, 8, 9, 10 and 11 , including all stereoisomers and pharmaceutical acceptable salts thereof,
Figure imgf000081_0001
Figure imgf000081_0002
wherein:
R1 is H, a branched or linear C1-C9 alkyl residue, a branched or linear C2-Cg alkenyl residue, a C3-C8 cycloalkyl- , C5-C7 cycloalkenyl-, aryl- or heteroaryl residue or a side chain of a natural amino acid or a derivative thereof, R3 and R4 are independently selected from H, hydroxy, alkyl, alkoxy, aryloxy, nitro, cyano or halogen,
A is H or an isoster of an carbonic acid, like a functional group selected from CN, SO3H,
CONHOH, PO3R -,5DR6, tetrazole, amide, ester, anhydride, thiazole and imidazole,
B is selected from:
Figure imgf000082_0001
wherein :
R5 is H, -(CH)n-NH-C5H3N-Y with n=2-4 and C5H3N-Y (a divalent pyridyl residue) with Y
= H, Br, Cl, I, NO2 or CN ,
R >10 is H, an acyl, oxycarbonyl or a amino acid residue ,
W is H or a phenyl or pyridyl residue, unsubstituted or substituted with one, two or more alkyl, alkoxy, halogen, nitro, cyano or carboxy residues,
W1 is H, an alkyl, alkoxy or phenyl residue,
Z is H or a phenyl or pyridyl residue, unsubstituted or substituted with one, two or more alkyl, alkoxy, halogen, nitro, cyano or carboxy residues,
Z1 is H or an alkyl residue, D is a cyclic C -C7 alkyl, C -C7 alkenyl residue which can be unsubstituted or substituted with one, two or more alkyl groups or a cyclic 4-7-membered heteroalkyl or a cyclic 4-7- membered heteroalkenyl residue,
X2 is O, NR6, N+(R7)2, or S,
X3 to X12 are independently selected from CH2, CR8R9, NR6, N+(R7)2, O, S, SO and SO2, including all saturated and unsaturated structures,
R6, R7, R8, R9 are independently selected from H, a branched or linear C1-C9 alkyl residue, a branched or linear C2-C9 alkenyl residue, a C3-C8 cycloalkyl residue, a C5-C7 cycloalkenyl residue, an aryl or heteroaryl residue,
with the following provisions:
Formula 6: X6 is CH if A is not H, Formula 7: X10 is C if A is not H, Formula 8: X7 is CH if A is not H, Formula 9: X12 is C if A is not H.
10. The use according to any one of claims 1 to 4, wherein the inhibitor of DPIV or DPIV-like enzyme activity is represented by the general formula,
A C
B
including all stereoisomers and pharmaceutical acceptable salts thereof,
wherein
A is an amino acid having at least one functional group in the side chain, B is a chemical compound covalently bound to at least one functional group of the side chain of A, especially
- an oligopeptide having a chain length of up to 20 amino acids, or
- a polyethylene glycol having a molar mass of up to 20 000 g/mol,
- an optionally substituted organic amine, amide, alcohol, acid or aromatic compound having from 8 to 50 C atoms and
C is a thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine group amide-bound to A.
11. The use according to claim 10, wherein A is an amino acid, preferably an α-amino acid, especially a natural α-amino acid having at least one functional group in the side chain selected from the group consisting of threonine, tyrosine, serine, arginine, lysine, aspartic acid, glutamic acid or cysteine.
12. The use according to any one of the preceding claims, wherein said inhibitor is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a said inhibitor or a pharmaceutically acceptable acid addition salt thereof.
13. The use according to any one of the preceding claims, wherein the inhibitor is used in combination with a pharmaceutically acceptable carrier and/or diluent.
PCT/EP2002/007133 2001-06-27 2002-06-27 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders WO2003002596A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2002328306A AU2002328306B8 (en) 2001-06-27 2002-06-27 Use of dipeptidyl peptidase IV inhibitors as therapeutics for neurological disorders
DE60224879T DE60224879D1 (en) 2001-06-27 2002-06-27 USE OF DPIV INHIBITORS AS A THERAPEUTICS FOR SICKNESS NEUROLOGICAL CONDITIONS
JP2003508976A JP2004534836A (en) 2001-06-27 2002-06-27 Novel use of dipeptidyl peptidase IV inhibitors
CA002424645A CA2424645A1 (en) 2001-06-27 2002-06-27 New use of dipeptidyl peptidase iv inhibitors
EP02762309A EP1399471B1 (en) 2001-06-27 2002-06-27 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders
NO20030895A NO20030895D0 (en) 2001-06-27 2003-02-26 New use of dipeptidyl peptidase IV inhibitors

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP01114796.4 2001-06-27
EP01114796 2001-06-27
DE10150203.6 2001-10-12
DE10150203A DE10150203A1 (en) 2001-10-12 2001-10-12 Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
DE10154689.0 2001-11-09
DE10154689A DE10154689A1 (en) 2001-11-09 2001-11-09 Substituted amino ketone compounds
US36090902P 2002-02-28 2002-02-28
US60/360,909 2002-02-28

Publications (2)

Publication Number Publication Date
WO2003002596A2 true WO2003002596A2 (en) 2003-01-09
WO2003002596A3 WO2003002596A3 (en) 2003-07-31

Family

ID=27438020

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/EP2002/007129 WO2003002595A2 (en) 2001-06-27 2002-06-27 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
PCT/EP2002/007133 WO2003002596A2 (en) 2001-06-27 2002-06-27 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders
PCT/EP2002/007124 WO2003072556A1 (en) 2001-06-27 2002-06-27 Glutaminyl based dpiv inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007129 WO2003002595A2 (en) 2001-06-27 2002-06-27 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007124 WO2003072556A1 (en) 2001-06-27 2002-06-27 Glutaminyl based dpiv inhibitors

Country Status (9)

Country Link
EP (2) EP1399471B1 (en)
JP (2) JP2004534836A (en)
CN (1) CN1321682C (en)
AT (1) ATE385238T1 (en)
AU (2) AU2002321135B2 (en)
CA (2) CA2424645A1 (en)
DE (1) DE60224879D1 (en)
NO (2) NO20030895D0 (en)
WO (3) WO2003002595A2 (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098625A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
WO2004104216A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007041368A2 (en) * 2005-09-30 2007-04-12 Novartis Ag Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
JP2007538079A (en) * 2004-05-18 2007-12-27 メルク　エンド　カムパニー　インコーポレーテッド Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP1961416A1 (en) 2003-05-05 2008-08-27 Probiodrug AG Medical use of inhibitors of glutaminyl and glutamate cyclases
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7723344B2 (en) 2003-08-13 2010-05-25 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7781584B2 (en) 2004-03-15 2010-08-24 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7825242B2 (en) 2004-07-16 2010-11-02 Takeda Pharmaceutical Company Limted Dipeptidyl peptidase inhibitors
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2289498A1 (en) 2003-10-15 2011-03-02 Probiodrug AG Use of inhibitors of glutaminyl clyclase
WO2011024110A3 (en) * 2009-08-27 2011-04-21 Rinat Neuroscience Corporation Glucagon-like peptide-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8124721B2 (en) 2005-10-04 2012-02-28 Inimex Pharmaceuticals Inc. Peptides for modulating innate immunity
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
EP4000630A1 (en) 2014-09-03 2022-05-25 Invex Therapeutics Ltd Elevated intracranial pressure treatment

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040015298A (en) 2001-06-27 2004-02-18 스미스클라인 비참 코포레이션 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
AU2003214534B2 (en) 2002-04-08 2006-08-31 Torrent Pharmaceuticals Ltd. Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
JP4806628B2 (en) 2003-05-05 2011-11-02 プロビオドルグ エージー Glutaminyl cyclase inhibitor
US20040229848A1 (en) * 2003-05-05 2004-11-18 Hans-Ulrich Demuth Glutaminyl based DP IV-inhibitors
JP2011201923A (en) * 2005-07-01 2011-10-13 Snow Brand Milk Products Co Ltd Dipeptidyl peptidase iv inhibitor
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (en) 2006-11-30 2012-05-15 Probiodrug Ag NEW INHIBITORS OF GLUTAMINYL CYCLASE
JP5667440B2 (en) 2007-04-18 2015-02-12 プロビオドルグ エージー Thiourea derivatives as glutaminyl cyclase inhibitors
JP5374058B2 (en) * 2008-03-12 2013-12-25 株式会社 資生堂 Glutamic acid derivative, keratinization inhibitor, pore reducing agent, rough skin prevention / improving agent, and composition for external use on skin
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2418196A1 (en) * 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
EP2782588B1 (en) * 2011-11-21 2020-04-15 Emmaus Medical, Inc. Methods and compositions for the treatment of diabetes and related symptoms
AU2014323008B2 (en) * 2013-09-23 2018-02-08 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Anti-inflammatory tripeptides
CN105343068A (en) * 2015-12-14 2016-02-24 上海壹志医药科技有限公司 Pharmacological purpose of sophocarpidine
TW201840582A (en) * 2017-03-21 2018-11-16 日商富士軟片股份有限公司 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound
CN107115348A (en) * 2017-05-31 2017-09-01 上海壹志医药科技有限公司 The medicinal usage of cucurbatacin E
CN107007612A (en) * 2017-05-31 2017-08-04 上海壹志医药科技有限公司 Cucurbitacin C medicinal usage
CN107375302A (en) * 2017-05-31 2017-11-24 上海壹志医药科技有限公司 The medicinal usage of Cucurbitacin B
CN107158006A (en) * 2017-05-31 2017-09-15 上海壹志医药科技有限公司 Cucurbitacin D medicinal usage
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors
JP7056702B2 (en) * 2020-09-15 2022-04-19 井関農機株式会社 Threshing device

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062914A1 (en) * 1998-06-05 1999-12-09 Point Therapeutics, Inc. Cyclic boroproline compounds
WO2001034594A1 (en) * 1999-11-12 2001-05-17 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
WO2001089569A1 (en) * 2000-05-23 2001-11-29 Institut Für Medizintechnologie Magdeburg Gmbh Imtm Combinations of enzyme inhibitor-containing preparations and the use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD296075A5 (en) * 1989-08-07 1991-11-21 Martin-Luther-Universitaet Halle-Wittenberg,De PROCESS FOR THE PREPARATION OF NEW INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE19823831A1 (en) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
DE19826972A1 (en) * 1998-06-18 1999-12-23 Univ Magdeburg Tech Inhibiting keratinocyte activation and proliferation, for treatment of dermatological disorders such as psoriasis or actinic precancerous states
IL141471A0 (en) * 1998-08-21 2002-03-10 Point Therapeutics Inc Regulation of substrate activity
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7785810B2 (en) * 2000-09-09 2010-08-31 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062914A1 (en) * 1998-06-05 1999-12-09 Point Therapeutics, Inc. Cyclic boroproline compounds
WO2001034594A1 (en) * 1999-11-12 2001-05-17 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
WO2001089569A1 (en) * 2000-05-23 2001-11-29 Institut Für Medizintechnologie Magdeburg Gmbh Imtm Combinations of enzyme inhibitor-containing preparations and the use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REINHOLD DIRK ET AL: "Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones." JOURNAL OF NEUROIMMUNOLOGY, vol. 87, no. 1-2, 1 July 1998 (1998-07-01), pages 203-209, XP002214116 ISSN: 0165-5728 *
STOCKEL-MASCHEK^A A ET AL: "Thioxo amino acid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases" BIOCHIMICA ET BIOPHYSICA ACTA. PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, ELSEVIER, AMSTERDAM,, NL, vol. 1479, no. 1-2, 15 June 2000 (2000-06-15), pages 15-31, XP004279023 ISSN: 0167-4838 *

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1961416A1 (en) 2003-05-05 2008-08-27 Probiodrug AG Medical use of inhibitors of glutaminyl and glutamate cyclases
WO2004098625A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
EP2206496A1 (en) 2003-05-05 2010-07-14 Probiodrug AG Medical use of inhibitors of glutaminyl and glutamate cyclases
DE202004021723U1 (en) 2003-05-05 2010-07-15 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
WO2004104216A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2004104216A3 (en) * 2003-05-21 2005-03-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7723344B2 (en) 2003-08-13 2010-05-25 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2289498A1 (en) 2003-10-15 2011-03-02 Probiodrug AG Use of inhibitors of glutaminyl clyclase
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7906523B2 (en) 2004-03-15 2011-03-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8329900B2 (en) 2004-03-15 2012-12-11 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8288539B2 (en) 2004-03-15 2012-10-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7781584B2 (en) 2004-03-15 2010-08-24 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8188275B2 (en) 2004-03-15 2012-05-29 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7807689B2 (en) 2004-03-15 2010-10-05 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8173663B2 (en) 2004-03-15 2012-05-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007538079A (en) * 2004-05-18 2007-12-27 メルク　エンド　カムパニー　インコーポレーテッド Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7825242B2 (en) 2004-07-16 2010-11-02 Takeda Pharmaceutical Company Limted Dipeptidyl peptidase inhibitors
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007041368A2 (en) * 2005-09-30 2007-04-12 Novartis Ag Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
AU2006297130B2 (en) * 2005-09-30 2009-12-24 Novartis Ag DPP IV inhibitor for use in the treatment of autoimmune diseases and graft rejection
WO2007041368A3 (en) * 2005-09-30 2007-10-25 Novartis Ag Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
US9416157B2 (en) 2005-10-04 2016-08-16 Soligenix, Inc. Peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
US8124721B2 (en) 2005-10-04 2012-02-28 Inimex Pharmaceuticals Inc. Peptides for modulating innate immunity
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
EP2253311A2 (en) 2006-04-11 2010-11-24 Arena Pharmaceuticals, Inc. Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
WO2011024110A3 (en) * 2009-08-27 2011-04-21 Rinat Neuroscience Corporation Glucagon-like peptide-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
EP4000630A1 (en) 2014-09-03 2022-05-25 Invex Therapeutics Ltd Elevated intracranial pressure treatment
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10772865B2 (en) 2015-03-09 2020-09-15 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11400072B2 (en) 2015-03-09 2022-08-02 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Also Published As

Publication number Publication date
AU2002328306B2 (en) 2007-09-06
WO2003072556A1 (en) 2003-09-04
EP1399471B1 (en) 2008-01-30
CA2424645A1 (en) 2003-01-09
ATE385238T1 (en) 2008-02-15
CA2418543A1 (en) 2003-01-09
AU2002321135B2 (en) 2007-11-08
EP1399470A2 (en) 2004-03-24
CN1321682C (en) 2007-06-20
WO2003002595A2 (en) 2003-01-09
DE60224879D1 (en) 2008-03-20
EP1399471A2 (en) 2004-03-24
WO2003002596A3 (en) 2003-07-31
CN1464881A (en) 2003-12-31
NO20030895L (en) 2003-02-26
NO20030896D0 (en) 2003-02-26
JP2004534836A (en) 2004-11-18
JP2004521149A (en) 2004-07-15
NO20030895D0 (en) 2003-02-26
AU2002328306B8 (en) 2008-02-21
WO2003002595A3 (en) 2003-05-08
NO20030896L (en) 2003-04-16

Similar Documents

Publication Publication Date Title
AU2002328306B2 (en) Use of dipeptidyl peptidase IV inhibitors as therapeutics for neurological disorders
AU2002328306A1 (en) Use of dipeptidyl peptidase IV inhibitors as therapeutics for neurological disorders
ZA200300595B (en) Use of dipeptidyl peptidase IV inhibitors.
US7368421B2 (en) Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030176357A1 (en) Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
AU2002321135A1 (en) Dipepitdyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368576B2 (en) Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
AU2002331224B2 (en) Peptidyl ketones as inhibitors of DPIV
WO2003015775A1 (en) New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels
US6946480B2 (en) Glutaminyl based DPIV inhibitors
AU2002331224A1 (en) Peptidyl ketones as inhibitors of DPIV
CENTER Pospisilik et al.(43) Pub. Date: Sep. 18, 2003
US20060194852A1 (en) Glutaminyl based DPIV inhibitors
NZ545366A (en) Glutaminyl based DPIV inhibitors
AU2002328305A1 (en) Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2424645

Country of ref document: CA

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002762309

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003/00595

Country of ref document: ZA

Ref document number: 200300595

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002328306

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2003 508976

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2003508976

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 028022475

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2002762309

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002762309

Country of ref document: EP